[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2181
1. Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, Thomas G, Fine HA, Linet MS, Rothman N, Chanock SJ, Inskip PD: Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1356-61
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The etiology of meningioma, the second most common type of adult brain tumor in the United States, is largely unknown.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):3131-8 [19234210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8 [19423540.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):427-35 [19560733.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2649-58 [10594860.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1185-95 [11063113.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):103-7 [12406554.001]
  • [Cites] Genet Epidemiol. 2003 Dec;25(4):360-6 [14639705.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] J Anat. 2005 Sep;207(3):265-9 [16185251.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):866-79 [16261174.001]
  • [Cites] Immunol Rev. 2006 Oct;213:195-212 [16972905.001]
  • [Cites] Pharmacogenet Genomics. 2006 Nov;16(11):783-8 [17047486.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):477-85 [17182979.001]
  • [Cites] Histol Histopathol. 2007 Dec;22(12):1387-98 [17701919.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50 [17925535.001]
  • [Cites] PLoS Genet. 2008 Aug;4(8):e1000166 [18846228.001]
  • [Cites] Dement Geriatr Cogn Disord. 2008;26(3):247-50 [18841008.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • (PMID = 20406964.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS184299; NLM/ PMC3169167
  •  go-up   go-down


2. Sagara J, Arata T, Taniguchi S: Scapinin, the protein phosphatase 1 binding protein, enhances cell spreading and motility by interacting with the actin cytoskeleton. PLoS One; 2009;4(1):e4247
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scapinin, also named phactr3, is an actin and protein phosphatase 1 (PP1) binding protein, which is expressed in the adult brain and some tumor cells.
  • At present, the role(s) of scapinin in the brain and tumors are poorly understood.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):241-56 [11839776.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):92-7 [11911886.001]
  • [Cites] Cell. 2003 Feb 21;112(4):453-65 [12600310.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Cell. 2003 May 2;113(3):329-42 [12732141.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45611-9 [12925532.001]
  • [Cites] Dev Biol. 2004 Jan 1;265(1):23-32 [14697350.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):1-39 [14715909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 4;101(18):7187-92 [15107502.001]
  • [Cites] Cell. 2004 May 28;117(5):611-23 [15163409.001]
  • [Cites] Trends Cell Biol. 2004 Jul;14(7):386-94 [15246432.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):614-25 [15366705.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):3973-83 [15385960.001]
  • [Cites] J Cell Biol. 1990 Jul;111(1):103-12 [2164027.001]
  • [Cites] J Biochem. 1991 Feb;109(2):335-40 [1864845.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):68-72 [9247125.001]
  • [Cites] Science. 1998 Jan 23;279(5350):509-14 [9438836.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1094-101 [15502823.001]
  • [Cites] FEBS Lett. 2005 Jan 3;579(1):100-4 [15620697.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):379-86 [16053508.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):967-71 [16549500.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):756-63 [16767080.001]
  • [Cites] Cytogenet Genome Res. 2006;115(1):23-9 [16974080.001]
  • [Cites] Trends Cell Biol. 2006 Nov;16(11):588-96 [17035020.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):37-48 [17183359.001]
  • [Cites] Science. 2007 Jun 22;316(5832):1749-52 [17588931.001]
  • [Cites] Dev Cell. 2007 Jul;13(1):87-102 [17609112.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1110-21 [17909522.001]
  • [Cites] J Cell Biol. 2007 Dec 17;179(6):1095-103 [18070915.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(2):732-42 [18025109.001]
  • (PMID = 19158953.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Nuclear Proteins; 0 / PHACTR3 protein, human; EC 3.1.3.16 / Protein Phosphatase 1
  • [Other-IDs] NLM/ PMC2626280
  •  go-up   go-down


3. Schubart JR, Kinzie MB, Farace E: Caring for the brain tumor patient: family caregiver burden and unmet needs. Neuro Oncol; 2008 Feb;10(1):61-72
MedlinePlus Health Information. consumer health - Caregivers.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caring for the brain tumor patient: family caregiver burden and unmet needs.
  • The rapid onset and progression of a brain tumor, cognitive and behavioral changes, and uncertainty surrounding prognosis are issues well known to health practitioners in neuro-oncology.
  • We studied the specific challenges that family caregivers face when caring for patients experiencing the significant neurocognitive and neurobehavioral disorders associated with brain tumors.
  • We selected 25 family caregivers of adult brain tumor patients to represent the brain tumor illness trajectory (crisis, chronic, and terminal phases).
  • [MeSH-major] Brain Neoplasms. Caregivers / statistics & numerical data. Cost of Illness. Family Relations
  • [MeSH-minor] Adult. Aged. Female. Health Services Needs and Demand. Humans. Male. Middle Aged. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Res Nurs Health. 2006 Apr;29(2):105-20 [16532486.001]
  • [Cites] Eur J Cancer Care (Engl). 1999 Jun;8(2):83-6 [10476110.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(4):225-31 [10473718.001]
  • [Cites] Patient Educ Couns. 2005 Jun;57(3):247-9 [15893205.001]
  • [Cites] Patient Educ Couns. 2005 Jun;57(3):250-61 [15893206.001]
  • [Cites] Patient Educ Couns. 2005 Jul;58(1):96-103 [15950842.001]
  • [Cites] Patient Educ Couns. 2005 Aug;58(2):182-6 [16009294.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):357-61 [10831342.001]
  • [Cites] Patient Educ Couns. 1999 Nov;38(3):217-25 [10865687.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3295-301 [10986063.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):152-8 [11465395.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(3):204-8 [11527297.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):61S-63S [11560975.001]
  • [Cites] Nurs Econ. 2002 Sep-Oct;20(5):216-21, 224 [12382538.001]
  • [Cites] Nurs Inq. 2004 Mar;11(1):43-53 [14962346.001]
  • [Cites] Cancer Nurs. 1989 Oct;12(5):285-92 [2804964.001]
  • [Cites] Oncol Nurs Forum. 1996 Sep;23(8):1247-56 [8883072.001]
  • [Cites] J Neurosci Nurs. 1998 Aug;30(4):245-52 [9791779.001]
  • [Cites] Support Care Cancer. 2006 Dec;14(12):1258-61 [16775683.001]
  • (PMID = 17993635.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2600839
  •  go-up   go-down


Advertisement
4. Lu Z, Zhou L, Killela P, Rasheed AB, Di C, Poe WE, McLendon RE, Bigner DD, Nicchitta C, Yan H: Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Res; 2009 Dec 1;69(23):9105-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.
  • Glioblastoma multiforme is the most prevalent type of adult brain tumor and one of the deadliest tumors known to mankind.
  • The genetic understanding of glioblastoma multiforme is, however, limited, and the molecular mechanisms that facilitate glioblastoma multiforme cell survival and growth within the tumor microenvironment are largely unknown.
  • The small interfering RNA-mediated knockdown of SEC61gamma expression in tumor cells led to growth suppression and apoptosis.
  • Together, these results indicate that aberrant expression of SEC61gamma serves significant roles in glioblastoma multiforme cell survival likely via a mechanism that is involved in the cytoprotective ER stress-adaptive response to the tumor microenvironment.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Clin Biol Res. 1994;385:51-7 [7972237.001]
  • [Cites] Nucleic Acids Res. 1994 Jan 25;22(2):187-93 [8121803.001]
  • [Cites] Genomics. 1996 Feb 15;32(1):97-103 [8786126.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Feb;15(2):134-7 [8834178.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):205-14 [8946202.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3322-31 [9345014.001]
  • [Cites] Oncogene. 1998 Jan 15;16(2):191-5 [9464536.001]
  • [Cites] Oncogene. 1998 May;16(20):2617-27 [9632138.001]
  • [Cites] J Cell Sci. 1999 May;112 ( Pt 10):1477-86 [10212142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8505-10 [10411905.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):966-77 [15573118.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2495-502 [15735698.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1374-81 [15845651.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3470-81 [16148948.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:529-50 [16212506.001]
  • [Cites] Mol Cancer Res. 2005 Nov;3(11):597-605 [16317085.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):374-84 [16397578.001]
  • [Cites] Mol Cancer Res. 2006 Mar;4(3):169-76 [16547154.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Mol Cancer Res. 2006 Jul;4(7):423-36 [16849518.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):721-2 [16880733.001]
  • [Cites] EMBO Rep. 2006 Sep;7(9):880-5 [16953201.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:487-508 [16822172.001]
  • [Cites] Trends Mol Med. 2006 Dec;12(12):567-73 [17071140.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):1064-72 [17215517.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29 [17565364.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9809-16 [17942911.001]
  • [Cites] Cell Mol Life Sci. 2008 Mar;65(6):862-94 [18038217.001]
  • [Cites] Bioessays. 2000 Aug;22(8):697-707 [10918300.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Nov;29(3):207-12 [10992295.001]
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):83-96 [11397666.001]
  • [Cites] Biochem Soc Trans. 2001 Aug;29(Pt 4):480-4 [11498013.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45307-19 [11535584.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):86-94 [11916499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16156-61 [12461184.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):723-7 [12566319.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 [14970324.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] J Neuropathol Exp Neurol. 1988 May;47(3):191-205 [3367154.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Genomics. 1992 May;13(1):16-20 [1349571.001]
  • [Cites] Genomics. 1992 May;13(1):21-4 [1315716.001]
  • [Cites] Cell Growth Differ. 1993 Dec;4(12):1065-70 [8117620.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):367-76 [7490069.001]
  • (PMID = 19920201.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA118822; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50 NS20023; United States / NCI NIH HHS / CA / R37 CA 011898; United States / NCI NIH HHS / CA / R01 CA118822-04; United States / NCI NIH HHS / CA / 5P50 CA108786; United States / NCI NIH HHS / CA / R01 CA118822; United States / NCI NIH HHS / CA / R37 CA011898; United States / NCI NIH HHS / CA / CA118822-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / SEC61G protein, human; 11089-65-9 / Tunicamycin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS151081; NLM/ PMC2789175
  •  go-up   go-down


5. Ferraz-Filho JR, Santana-Netto PV, Rocha-Filho JA, Sgnolf A, Mauad F, Sanches RA: Application of magnetic resonance spectroscopy in the differentiation of high-grade brain neoplasm and inflammatory brain lesions. Arq Neuropsiquiatr; 2009 Jun;67(2A):250-3
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of magnetic resonance spectroscopy in the differentiation of high-grade brain neoplasm and inflammatory brain lesions.
  • This study aims at evaluating the application of magnetic resonance spectroscopy (MRS) in the differential diagnosis of brain tumors and inflammatory brain lesions.
  • The examinations of 81 individuals, who performed brain MRS and were retrospectively analyzed.
  • Group A consisted of 42 individuals with diagnoses of cerebral toxoplasmosis and Group B was formed of 39 individuals with diagnosis of glial neoplasms.
  • On analyzing the ROC curve, the discriminatory boundary for the Cho/Cr ratio between inflammatory lesions and tumors was 1.97 and for the NAA/Cr ratio it was 1.12.
  • RMS is an important method useful in the distinction of inflammatory brain lesions and high-degree tumors when the Cho/Cr ratio is greater than 1.97 and the NAA/Cr ratio is less than 1.12.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy. Toxoplasmosis, Cerebral / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547817.001).
  • [ISSN] 1678-4227
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


6. Rezanko T, Tunakan M, Kahraman A, Sucu HK, Gelal F, Akkol I: Primary rhabdoid tumor of the brain in an adult. Neuropathology; 2006 Feb;26(1):57-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rhabdoid tumor of the brain in an adult.
  • Rhabdoid tumor (RT) is an uncommon childhood neoplasm that typically arises within the kidney.
  • The first case in the CNS was reported in 1985 and was defined as "rhabdoid tumor" initially, and was classified as grade IV in the most recent classification of the World Health Organization under the term of "atypical teratoid/rhabdoid tumor".
  • Nearly 200 cases of atypical teratoid/rhabdoid tumor of the CNS have been reported to date, most of them occurring in childhood.
  • We report a case of primary RT of the brain located in the right frontal lobe with the clinical, radiographic and pathological features presenting at an unusual age.
  • This tumor, which was composed purely of rhabdoid cells with no additional primitive neuroectodermal, epithelial and mesenchymal components, was in a 27-year-old male patient.
  • In conclusion, RT should be considered also in the differential diagnosis of intracerebral neoplasms of adult patients.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Meningioma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Ferrer S: [Radiation therapy with synchrotron radiation and cisplatin-based chemotherapy as a treatment of gliomas]. Med Clin (Barc); 2005 Feb 26;124(7):271-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esteve has been working for several years in the Grenoble Synchrotron (ESRF) on radiotherapy treatments to heal brain tumors.
  • Gliomas the commonest brain tumor in the adult and the mean survival in advanced disease patients is lower than one year.
  • Conventional radiation therapy is used palliatively since it is one of the most radiotherapy-resistant tumors.
  • Experiments at the Grenoble Synchrotron have been carried out in mice with gliomas and they consist of injecting cysplatine into the tumors so that an intense monochromatic radiation is applied afterwards.
  • After one year of treatment, 34% of animals remain alive, which constitutes a result never seen before in this type of radio-resistant tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cisplatin / therapeutic use. Glioma / drug therapy. Glioma / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743595.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Young GS: Advanced MRI of adult brain tumors. Neurol Clin; 2007 Nov;25(4):947-73, viii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced MRI of adult brain tumors.
  • This article is intended to provide clinical neurologists with an overview of the major techniques of advanced MRI of brain tumor: diffusion-weighted imaging, perfusion-weighted imaging, dynamic contrast-enhanced T1 permeability imaging, diffusion-tensor imaging, and magnetic resonance spectroscopy.
  • These techniques represent a significant addition to conventional anatomic MRI T2-weighted images, fluid attenuated inversion recovery (FLAIR) T2-weighted images, and gadolinium-enhanced T1-weighted images for assessing tumor cellularity, white matter invasion, metabolic derangement including hypoxia and necrosis, neovascular capillary blood volume, and permeability.
  • Although a brief introduction and more extensive references to the technical literature is provided, the major focus is to provide a summary of recent clinical experience in application of these major advanced MRI techniques to differential diagnosis, grading, surgical planning, and monitoring of therapeutic response of tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Magnetic Resonance Spectroscopy. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964022.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


9. Padovani L, André N, Carrie C, Muracciole X: [Childhood and adult medulloblastoma: what difference?]. Cancer Radiother; 2009 Oct;13(6-7):530-5
Genetic Alliance. consumer health - Medulloblastoma, childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood and adult medulloblastoma: what difference?].
  • Medulloblastoma is the most frequent childhood brain tumor (30%) but account only for less than 1% of adult brain tumor.
  • Due to the rarety in adult population, no prospective studies and few data about late effects are available.
  • Adult medulloblastoma is a therapeutic challenge and their therapeutic strategies are similar to pediatric protocols.
  • In order to improve the understanding of adult disease and to homogenize the treatment, National Cancer Institute (INCa) stimulated the creation of web conference to discuss each case prospectively and to propose a protocol of treatment.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / epidemiology. Child. Cognition Disorders / epidemiology. Cognition Disorders / etiology. Combined Modality Therapy. France / epidemiology. Humans. Incidence. Molecular Biology / methods. Radiotherapy / adverse effects. Radiotherapy / methods. Surgical Procedures, Operative

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713143.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y, Tsavachidis S, Ahlbom A, Auvinen A, Collatz-Laier H, Feychting M, Johansen C, Kiuru A, Lönn S, Schoemaker MJ, Swerdlow AJ, Henriksson R, Bondy M, Melin B: A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol; 2010 Aug;49(6):767-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioma is the most common type of adult brain tumor and glioblastoma, its most aggressive form, has a dismal prognosis.
  • Receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR, ERBB2, ERBB3, ERBB4) family, and the vascular endothelial growth factor receptor (VEGFR), play a central role in tumor progression.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Polymorphism, Single Nucleotide. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Denmark. England. Female. Finland. Genotype. Haplotypes. Humans. Linkage Disequilibrium. Male. Middle Aged. Risk Assessment. Risk Factors. Sweden


11. Yamane T, Sakamoto S, Senda M: Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging; 2010 Apr;37(4):685-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm.
  • PURPOSE: We retrospectively examined the clinical efficacy of (11)C-methionine positron emission tomography ((11)C-MET PET) in patients with brain neoplasm, especially whether the (11)C-MET PET changed the clinical management and whether the change was beneficial or detrimental.
  • METHODS: This study reviewed 89 (11)C-MET PET scans for 80 patients (20 scans for initial diagnosis of brain tumor and 69 scans for differentiating tumor recurrence from radiation necrosis).
  • CONCLUSION: (11)C-MET PET can provide useful information in initial diagnosis and differentiating tumor recurrence from radiation necrosis.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Carbon Radioisotopes. Glioma / diagnostic imaging. Methionine. Patient Care Planning. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / diagnostic imaging. Brain / radiation effects. Carcinoma / diagnostic imaging. Carcinoma / secondary. Child. Decision Making. Diagnosis, Differential. False Negative Reactions. Female. Humans. Lymphoma, Non-Hodgkin / diagnostic imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnostic imaging. Radiation Injuries / diagnostic imaging. Radiotherapy / adverse effects. Sensitivity and Specificity. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):683-4 [20107786.001]
  • [ErratumIn] Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):831
  • [Cites] Jpn J Clin Oncol. 2009 May;39(5):297-302 [19269991.001]
  • [Cites] J Nucl Med. 2008 Oct;49(10):1593-600 [18794254.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] J Neurosurg. 2004 Sep;101(3):476-83 [15352606.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):1967-72 [16155144.001]
  • [Cites] Cancer. 2001 Sep 15;92 (6):1541-9 [11745233.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Dec;34(12 ):1933-42 [17763848.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):305-14 [17492401.001]
  • [Cites] Neuroradiology. 1992;34(6):517-9 [1436463.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Nov;29(10 ):1867-71 [18687745.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1451-7 [18703607.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1064-72 [15014903.001]
  • [Cites] J Neurooncol. 2009 Jun;93(2):233-41 [19099197.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):714-22 [19095373.001]
  • [Cites] Acta Neurochir (Wien). 2002 Aug;144(8):777-82; discussion 782 [12181686.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2155-61 [18362365.001]
  • [Cites] J Nucl Med. 2008 May;49(5):694-9 [18413375.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1176-82 [18388218.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):901-9 [10815666.001]
  • [Cites] Mol Imaging Biol. 2008 Sep;10(5):281-7 [18543041.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Clin Neurosci. 2000 Nov;7(6):475-83 [11029226.001]
  • [Cites] Neurosurgery. 2004 May;54(5):1111-7; discussion 1117-9 [15113465.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):823-9 [11564242.001]
  • [Cites] J Nucl Med. 2007 Dec;48(12 ):1971-80 [18006617.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):354-61 [18931839.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Ann Nucl Med. 2004 Jun;18(4):291-6 [15359921.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2009-17 [18542957.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):347-53 [18931840.001]
  • (PMID = 19915838.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


12. Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. J Clin Oncol; 2009 May 20;27(15_suppl):2060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults.
  • METHODS: We retrospectively identified adults treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.
  • Bevacizumab (5-10 mg/kg) every other week was combined with cytotoxic agents: irinotecan (3), carboplatin (2), or temozolomide (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Horbinski C, Mintz A, Engh J, Lieberman F, Hamilton RL, Park DM: Post-therapeutic changes in the molecular profile of glioblastomas. J Clin Oncol; 2009 May 20;27(15_suppl):2026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2026 Background: Glioblastoma multiforme is the most common and malignant primary brain tumor in adults.
  • Analyses were performed on tumor tissue obtained at initial diagnosis and at first recurrence.
  • 24% of previously non-EGFR-amplified tumors acquired low-grade amplification (less than 10 copies/chromosome 7 CEP signal) after treatment, and 16% of EGFR-amplified tumors lost amplification after treatment.
  • CONCLUSIONS: Our results suggest that the molecular profile of these tumors is dynamic and that certain key alterations, including acquisition of low-level EGFR amplification in previously EGFR-negative tumors, occurs in a subset of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Zitron IM, Norkina O, Al-Kadhimi Z, Barger GR, Lum LG, Mittal S: Targeting of glioblastoma with activated T cells armed with anti-CD3xanti-HER2/neu (HER2Bi) and anti-CD3xanti-EGFR (EGFRBi) bispecific antibodies. J Clin Oncol; 2009 May 20;27(15_suppl):3038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3038 Background: Malignant gliomas are the most common primary brain tumors in adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962074.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Panchal NJ, Niku S, Imbesi SG: Lymphocytic vasculitis mimicking aggressive multifocal cerebral neoplasm: mr imaging and MR spectroscopic appearance. AJNR Am J Neuroradiol; 2005 Mar;26(3):642-5
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocytic vasculitis mimicking aggressive multifocal cerebral neoplasm: mr imaging and MR spectroscopic appearance.
  • We present a case of multifocal enhancing lesions confined to the right cerebral hemisphere that mimicked diffuse neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphocytes / pathology. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Vasculitis, Central Nervous System / diagnosis
  • [MeSH-minor] Adult. Brain / metabolism. Brain / pathology. Choline / metabolism. Diagnosis, Differential. Female. Glutamic Acid / metabolism. Glutamine / metabolism. Humans


16. Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, Jacobs AH, Heiss WD: [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol; 2010 Jan;96(2):231-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors.
  • Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain neoplasm.
  • The MET tumor-uptake relative to a corresponding control region was calculated.
  • A receiver operating characteristic (ROC) was performed to determine the MET-uptake value that best distinguishes tumorous from non-tumorous brain lesions.
  • A differentiation between tumorous (n = 39) and non-tumorous brain lesions (n = 9) was possible at a threshold of 1.48 of relative MET-uptake with a sensitivity of 83% and a specificity of 92%, respectively.
  • A differentiation between high grade malignant lesions (mean MET-uptake = 2.00 +/- 0.46) and low grade tumors (mean MET-uptake = 1.84 +/- 0.31) was not possible.
  • MET-PET might be a useful tool to differentiate tumorous from non-tumorous lesions in children and young adults when a decision for further therapy is difficult or impossible from routine structural imaging procedures alone.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Methionine / analogs & derivatives. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging / methods. Male. ROC Curve. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol. 1987 Nov-Dec;28(6):673-81 [2962599.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] Pediatr Neurol. 1990 May-Jun;6(3):163-70 [2193641.001]
  • [Cites] J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13 [1522276.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):110-8 [8282858.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):349-53 [8599907.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):387-93 [8667081.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24 [16450140.001]
  • [Cites] Childs Nerv Syst. 2007 Jul;23(7):739-51 [17356889.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] Pediatr Neurosurg. 2003 Mar;38(3):146-55 [12601239.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1389-97 [12920486.001]
  • [Cites] J Neuroimaging. 2004 Oct;14(4):372-6 [15358961.001]
  • [Cites] Int J Appl Radiat Isot. 1979 Jul;30(7):393-9 [478664.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • (PMID = 19575148.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester
  • [Other-IDs] NLM/ PMC2808525
  •  go-up   go-down


17. Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC: Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol; 2005 Oct;64(10):875-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma.
  • We present 8 examples of a neoplasm with features of both astrocytoma and ependymoma that may represent a distinct clinicopathologic entity.
  • The cerebral hemispheric tumors occurred in patients that were 3, 4, 12, 14, 15, 26, 30, and 37 years of age.
  • Histologically, the variably infiltrative tumors were distinctively angiocentric with well-developed perivascular pseudorosettes in some cases.
  • Overall, the tumors were biologically indolent except for one that recurred and ultimately proved fatal.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Ependymoma / pathology. Epilepsy / etiology. Glioma / complications. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy, Electron. Mucin-1 / metabolism


18. Saito T, Sugiyama K, Yamasaki F, Tominaga A, Kurisu K, Takeshima Y, Hirose T: Familial occurrence of dysembryoplastic neuroepithelial tumor-like neoplasm of the septum pellucidum: case report. Neurosurgery; 2008 Aug;63(2):E370-2; discussion E372
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial occurrence of dysembryoplastic neuroepithelial tumor-like neoplasm of the septum pellucidum: case report.
  • OBJECTIVE: Dysembryoplastic neuroepithelial tumor (DNT)-like neoplasms of the septum pellucidum are extremely rare.
  • In this article, we report the familial occurrence of these neoplasms.
  • CLINICAL PRESENTATION: We report two cases of such neoplasms: Patient 1, a 42-year-old woman, and Patient 2, the 20-year-old nephew of Patient 1.
  • In both cases, magnetic resonance imaging (MRI) revealed an intraventricular tumor adjacent to the septum pellucidum.
  • Both tumors appeared as a hypointense region on T1-weighted MRI, and both appeared as a hyperintense region on T2-weighted MRI without gadolinium enhancement.
  • Interestingly, both tumors had a high apparent diffusion coefficient.
  • INTERVENTION: Both tumors were subtotally removed and had common histological findings, such as alveolar structures with oligodendroglia-like cells and "specific glioneuronal element."
  • These findings are consistent with a dysembryoplastic neuroepithelial tumor-like neoplasm.
  • After tumor removal, the symptoms disappeared.
  • MRI showed no regrowth of residual tumors at 4 years (Patient 1) and 2 years (Patient 2) postoperatively.
  • CONCLUSION: The familial occurrence of this rare tumor suggests that both of these cases arose from a common germline mutation.
  • Identification of this rare tumor in this rare location is important to avoid unnecessary adjuvant therapy.
  • A markedly high apparent diffusion coefficient and histological findings of specific glioneuronal element can facilitate the differential diagnosis of dysembryoplastic neuroepithelial tumor-like neoplasms.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / genetics. Septum Pellucidum / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Pedigree

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797318.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR: Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol; 2008 May;88(1):65-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.
  • OBJECTIVES: We evaluated and compared tumor antigen precursor protein (TAPP) profiles in adult and pediatric brain tumors of 31 genes related to tumor associated antigens (TAA) for possible use in immunotherapy.
  • Antigens were selected based on their potential to stimulate T cell responses against tumors of neuroectodermal origin.
  • METHODS: Thirty-seven brain tumor specimens from 11 adult and 26 pediatric patients were analyzed by quantitative real-time PCR for the relative expression of 31 TAPP mRNAs.
  • The age range of adults (4F:7M) was 27-77 years (median 51.5 +/- 14.5 years) and for pediatrics (12F:14M) was 0.9-19 years (median 8.3 +/- 5.5 years).
  • RESULTS: The adult gliomas expressed 94% (29 of 31) of the TAPP mRNAs evaluated compared with pediatric brain tumors that expressed 55-74% of the TAPP mRNAs, dependent on tumor histological subtype.
  • (1) equal expression among adult and pediatric cases, (2) greater expression in adult than pediatric cases, (3) expression restricted to adult GBM and (4) a random distribution.
  • The pediatric brain tumors lacked expression of some genes associated with engendering tumor survival, such as hTert and Survivin.
  • CONCLUSIONS: The potential TAA targets identified from the TAPP profiles of 31 genes associated with adult and pediatric brain tumors may help investigators select specific target antigens for developing dendritic cell- or peptide-based vaccines or T cell-based immunotherapeutic approaches against brain tumors.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):337-44 [11676393.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] J Cell Biol. 1989 Dec;109(6 Pt 1):2575-87 [2687284.001]
  • [Cites] Hum Gene Ther. 1995 May;6(5):591-601 [7578396.001]
  • [Cites] Cancer Immunol Immunother. 1997 Oct;45(2):77-87 [9390198.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):882-3 [9525374.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):42-51 [9647171.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1359-65 [9880507.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Neuro Oncol. 2005 Jul;7(3):225-35 [16053697.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):342-63 [16389946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202 [16492905.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):4-13 [16534789.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1555-60 [16685456.001]
  • [Cites] Neurosurg Focus. 2000;9(6):e9 [16817692.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):905-13 [16957584.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1052-60 [16826191.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):139-48 [17004103.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-75 [17255279.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4960-3 [17785545.001]
  • [Cites] Immunology. 2007 Dec;122(4):615-22 [17645496.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):617-23 [10698506.001]
  • [Cites] J Neurooncol. 1999;45(2):141-57 [10778730.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2209-18 [10873070.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • (PMID = 18259692.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121258; United States / NINDS NIH HHS / NS / NS 046463; United States / NCI NIH HHS / CA / CA 121258; United States / NINDS NIH HHS / NS / R21 NS057829; United States / NINDS NIH HHS / NS / NS 054093; United States / NINDS NIH HHS / NS / NS 056300; United States / NINDS NIH HHS / NS / R21 NS056300; United States / NINDS NIH HHS / NS / R21 NS046463; United States / NINDS NIH HHS / NS / NS 057829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS572988; NLM/ PMC4005736
  •  go-up   go-down


20. Li YZ, Huang ZL, Wei DN, Xie CM, He HQ, Wei YF, Chen L, Wu PH: [Diffusion tensor imaging of the white matter tracts in preoperative patients with cerebral neoplasm]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov;26(11):1648-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffusion tensor imaging of the white matter tracts in preoperative patients with cerebral neoplasm].
  • OBJECTIVE: To evaluate the quantitative relationship between white matter tract (WMT) variation resulting from cerebral tumors and shifting of the fractional anisotropy (FA) index in magnetic resonance (MR) diffusion tensor imaging (DTI).
  • METHODS: Four female and 8 male patients aged from 21 to 62 years with brain malignancies (2 malignant lymphomas, 2 low-grade astrocytomas, and 8 high-grade cerebral gliomas) underwent conventional contrast-enhanced MR and DTI examinations before operation.
  • The DTI patterns in WMT altered by the tumor were categorized on the basis of FA1/FA2 ratio as follows: pattern 1, FA1/FA2> or =75% with normal or only slightly decreased FA; pattern 2, 50%< or =FA1/FA2<75% with WMT displacement; pattern 3, 25%< or =FA1/FA2/50% with WMT involvement; pattern 4, FA1/FA2<25% with WMT destruction.
  • CONCLUSIONS: DTI allows for visualization of WMT and benefits surgical planning for patients with intrinsic brain tumor.
  • There is a positive relationship between the bilateral FA ratio (FA1/FA2) variation and WMT alterations resulting from the tumor.
  • [MeSH-major] Brain / radiography. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Female. Glioblastoma / diagnosis. Glioma / diagnosis. Humans. Male. Middle Aged. Nerve Fibers / radiography. Neural Pathways / radiation effects. Preoperative Care. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121724.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, Mikheev AM, Horner PJ, Rostomily RC: Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia; 2009 Apr 1;57(5):510-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
  • The capacity of adult human glial progenitor cells (AGPs), to proliferate and undergo multipotent differentiation, positions them as ideal candidate cells of origin for human gliomas.
  • To investigate this potential role we identified AGPs as mitotically active Olig2 cells in nonneoplastic adult human brain and gliomas.
  • Extrapolating from a mean Olig2/Mib-1 labeling index (LI) of 52% and total cell number of 100 billion, we estimated the overall prevalence of mitotic Olig2 AGPs in nonneoplastic human brain parenchyma at 10 million.
  • The novel framework provided by this quantitative and comparative analysis supports future studies to examine the histogenetic role of Olig2 AGPs in adult gliomas, their potential contribution to the tumor stroma and the molecular role of Olig2 in glioma pathogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18837053.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007144; United States / NINDS NIH HHS / NS / T32 NS007144-25; United States / NINDS NIH HHS / NS / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS 0007144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / MIB-1 antibody; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human
  • [Other-IDs] NLM/ NIHMS77469; NLM/ PMC4415884
  •  go-up   go-down


22. Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, Krejza J, Rosenfeld MR, O'Rourke DM, Lustig R, Melhem ER, Wolf RL: Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology; 2009 Mar;250(3):887-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
  • PURPOSE: To determine the accuracy of relative cerebral blood volume (rCBV) fraction for distinguishing high-grade recurrent neoplasm from treatment-related necrosis (TRN) in enhancing masses identified on surveillance magnetic resonance (MR) images following treatment for primary or secondary brain neoplasm.
  • CONCLUSION: The fraction of malignant histologic features in enhancing masses recurring after treatment for brain neoplasms can be predicted by using the rCBV fraction, with improved differentiation between recurrent neoplasm and TRN.
  • [MeSH-major] Blood Volume. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Cerebrovascular Circulation. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Discriminant Analysis. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2009
  • (PMID = 19244052.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Meling TR, Helseth E, Unsgård G, Nakstad PH, Wester K: [Brain metastases in adults]. Tidsskr Nor Laegeforen; 2005 Aug 25;125(16):2179-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain metastases in adults].
  • BACKGROUND AND METHODS: Brain metastases are far more common than primary central nervous system tumours.
  • RESULTS: Brain metastases are caused by haematogenous spread from extracranial tumours, most frequently from cancers in the lung, breast, melanoma, renal carcinomas and colorectal carcinomas.
  • Three out of four patients present with multiple brain metastases.
  • INTERPRETATION: Some patients are offered neurosurgical treatment (surgery or gamma knife), depending on their clinical status, the number and location of brain metastases, and the histology and degree of systemic involvement of the primary tumour.
  • The gamma knife is the treatment of choice with multiple and solitary tumours smaller than 3 cm that lie deep within the brain or within eloquent areas, whereas surgery is the treatment of choice with solitary metastases larger than 3-3.5 cm that are surgically accessible and cause significant mass effects.
  • [MeSH-major] Brain Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Prognosis. Radiosurgery. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138130.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


24. Yamamoto M: Radiosurgery for metastatic brain tumors. Prog Neurol Surg; 2007;20:106-28
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for metastatic brain tumors.
  • New, not yet widely known concepts pertaining to Gamma Knife (GK) radiosurgery for brain metastases are reviewed.
  • Though lesion size is a limitation, high tumor control rates are possible when 1-4 lesions are irradiated with <or=20 Gy.
  • Symptomatic complications, i.e. radionecrosis of normal brain tissues, are slightly more common in long-surviving patients.
  • However, since most patients die of causes other than metastatic brain disease, i.e. before long-term complications manifest, good brain function is usually maintained till death.
  • Although some studies found retreatment for new lesions to be less frequent when whole brain radiotherapy (WBRT) is combined with surgery or GK radiosurgery, in our experience neither survival nor local recurrence rates improve significantly with WBRT.
  • Advantages of GK over WBRT include brief hospitalization, higher control rates, better symptom palliation, all MRI-detected lesions can be treated, other treatments (e.g. radiotherapy) need not be postponed, irradiation can be repeated, the incidence of dementia (due to radionecrosis) is far lower and more tumors (30+) can be treated in one session.
  • We advocate meticulous MRI follow-up to detect recurrence and assess tumor necrosis.
  • All detectable tumors should be irradiated, so long as the patient wishes to continue treatment.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Mental Disorders / epidemiology. Mental Disorders / etiology. Middle Aged. Neoplasm Metastasis. Postoperative Complications / epidemiology. Sensitivity and Specificity. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317980.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Krummert B, Scherer K, Whitley J, Sirelkhatim A, Panda M: A rare cause of seizure masquerading as neoplasm. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of seizure masquerading as neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebrum / blood supply. Cerebrum / pathology. Epilepsy, Tonic-Clonic / etiology. Vasculitis, Central Nervous System / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cerebral Angiography. Diagnosis, Differential. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neurologic Examination. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1494-6 [10584789.001]
  • [Cites] J Assoc Physicians India. 2002 Jul;50:977-8 [12126361.001]
  • [Cites] Medicine (Baltimore). 1988 Jan;67(1):20-39 [3275856.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Sep;51(9):1126-33 [2906362.001]
  • [Cites] Cleve Clin J Med. 1992 May-Jun;59(3):293-306 [1516217.001]
  • [Cites] Semin Neurol. 1994 Dec;14(4):341-8 [7709084.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Mar;26(3):642-5 [15760879.001]
  • [Cites] Rev Neurol (Paris). 2005 Sep;161(8-9):836-9 [16244567.001]
  • [Cites] J Child Neurol. 2006 Jul;21(7):623-5 [16970859.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1732-5 [18625623.001]
  • (PMID = 22798309.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029657
  •  go-up   go-down


26. Ghaemmaghami F, Behtash N, Ayatollahi H, Hanjani P: Successful treatment of two patients with gestational trophoblastic neoplasm presenting with emergent neurologic symptoms. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):937-40
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of two patients with gestational trophoblastic neoplasm presenting with emergent neurologic symptoms.
  • The objective of this study is to present the successful treatment of two young patients with gestational trophoblastic neoplasms (GTN) presenting with emergent neurologic symptoms without any gynecological problems.
  • Case 2, a 33-year-old patient, underwent craniotomy due to hemorrhagic brain tumor in the neurosurgery department.
  • It seems that multiagent chemotherapy in conjunction with whole-brain irradiation results in acceptable survival rate in brain metastatic GTN patients.
  • [MeSH-major] Brain Neoplasms / therapy. Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Adult. Female. Humans. Pregnancy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681792.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precancerous lesion with a well-described progression to carcinoma.
  • Phenotypic manifestations of Lynch syndrome in this patient included multiple adenomas and adenocarcinomas of the colon and also several other Lynch syndrome-associated cancers.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


28. Yoshida S: Brain metastasis in patients with esophageal carcinoma. Surg Neurol; 2007 Mar;67(3):288-90
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis in patients with esophageal carcinoma.
  • BACKGROUND: Brain metastasis from esophageal carcinoma is rare, and its natural history is unclear.
  • METHODS: We treated 803 patients with metastatic brain tumors, and there were 17 patients with brain metastases from esophageal carcinoma.
  • RESULTS: In the 15 patients with the pretreatment KPS of 70 or higher, the median survival after the diagnosis of brain metastasis was 26.2 months.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Carcinoma / secondary. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neurosurgical Procedures. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320640.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • While randomized comparisons assessing tumor recurrence, quality of life, or survival are the ideal means of comparing treatments, it can be difficult to recruit patients to such trials and lengthy follow-up periods are needed because of the slowly progressive natural history of these tumors.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-major] Brain Neoplasms / therapy. Evidence-Based Medicine
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


30. Arita K, Hirano H, Tominaga A, Kurisu K: [Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD]. Brain Nerve; 2008 Dec;60(12):1445-54
Genetic Alliance. consumer health - Growth Hormone Deficiency.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD].
  • Adult growth hormone deficiency (aGHD) has been widely accepted in endocrinological practice.
  • Traumatic brain injury and subarachnoid hemorrhage have, however, been emerging as important etiologies of aGHD in recent years.
  • Considering the high incidences of these brain injuries and significant rate of hypopituitarism in the survivors, the impact of aGHD on public health should be much larger than it is generally considered.
  • Although there is no evidence to prove that GH replacement increases the risk of recurrence of tumor, de-novo neoplasm, or serious cardiovascular disease, the long-term safety of GH replacement should be rigorously monitored.
  • [MeSH-minor] Adult. Brain Injuries / complications. Hormone Replacement Therapy. Humans. Hypopituitarism / complications. Quality of Life. Subarachnoid Hemorrhage / complications

  • Genetic Alliance. consumer health - Adult Growth Hormone Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110756.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  • [Number-of-references] 29
  •  go-up   go-down


31. Ashraf-Ganjooei T, Ghaemmaghami F: Patients with presenting unusual manifestations with gestational trophoblastic neoplasm: case series and review of literatures. Arch Gynecol Obstet; 2008 May;277(5):465-70
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for trophoblastic neoplasm .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with presenting unusual manifestations with gestational trophoblastic neoplasm: case series and review of literatures.
  • Early recognition of gestational trophoblastic neoplasms (GTN) will maximize the chances of cure with chemotherapy but some patients present with many different symptoms months or even years after the causative pregnancy making diagnosis difficult.
  • Clinicians should be aware of the possibility of GTN in any reproductive age woman with bizarre central nervous system symptoms, gastrointestinal symptoms or radiographic evidence of metastatic tumor of unknown primary origin.
  • We reported two cases of metastatic gestational trophoblastic neoplasms with bizarre pulmonary symptoms, one patient with small bowel metastasis, and two patients with brain metastasis presenting with unusual manifestations.
  • [MeSH-major] Brain Neoplasms / diagnosis. Digestive System Neoplasms / diagnosis. Gestational Trophoblastic Disease / diagnosis. Kidney Neoplasms / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Pregnancy


32. Siker ML, Mehta MP: Resection versus radiosurgery for patients with brain metastases. Future Oncol; 2007 Feb;3(1):95-102
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection versus radiosurgery for patients with brain metastases.
  • Brain metastases occur in 20-40% of adult cancer patients and the incidence is apparently increasing.
  • Whole brain radiation therapy is the standard of care for most patients with brain metastases.
  • In addition to focal treatments, future directions in the treatment of brain metastases include the development of intraoperative imaging capabilities, improved methods of identifying patients who are likely to benefit from treatment, systemic agents, such as chemotherapy and radiosensitizers, and the incorporation of targeted and antiangiogenic therapies.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280506.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 44
  •  go-up   go-down


33. Matsumoto L, Yamamoto T, Higashihara M, Sugimoto I, Kowa H, Shibahara J, Nakamura K, Shimizu J, Ugawa Y, Goto J, Dalmau J, Tsuji S: Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Mov Disord; 2007 Apr 15;22(5):728-31
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes.
  • The young age of the patient, along with progressive neurologic deterioration, detection of anti-Ma2 antibodies, and ultrasound findings of bilateral microcalcifications, led to bilateral orchiectomy, revealing the tumor in both testes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Neurol. 2006 Oct;2(10):566-72; quiz 573 [16990830.001]
  • [Cites] Ann Neurol. 2001 Sep;50(3):339-48 [11558790.001]
  • [Cites] N Engl J Med. 1999 Jun 10;340(23):1788-95 [10362822.001]
  • [Cites] Brain. 1994 Aug;117 ( Pt 4):859-76 [7922471.001]
  • [Cites] Mov Disord. 1993 Jul;8(3):321-6 [8341296.001]
  • [Cites] Urology. 1992 Nov;40(5):464-7 [1441049.001]
  • [Cites] Brain. 2004 Aug;127(Pt 8):1831-44 [15215214.001]
  • [Cites] Radiology. 2002 Aug;224(2):425-8 [12147838.001]
  • [Cites] J Neurol Sci. 1991 Mar;102(1):76-82 [1856734.001]
  • [Cites] Eur Urol. 2002 Jun;41(6):651-4 [12074783.001]
  • (PMID = 17269131.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089054-05; United States / NCI NIH HHS / CA / CA107192-03; United States / NCI NIH HHS / CA / R01 CA107192; United States / NCI NIH HHS / CA / CA089054-05; United States / NCI NIH HHS / CA / R01 CA089054; United States / NCI NIH HHS / CA / R01 CA107192-03
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ NIHMS24643; NLM/ PMC1909751
  •  go-up   go-down


34. Liu Q, Liu R, Kashyap MV, Agarwal R, Shi X, Wang CC, Yang SH: Brainstem glioma progression in juvenile and adult rats. J Neurosurg; 2008 Nov;109(5):849-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem glioma progression in juvenile and adult rats.
  • OBJECT: Brainstem gliomas are common in children and have the worst prognosis of any brain tumor in this age group.
  • On the other hand, brainstem gliomas are rare in adults, and the authors of some clinical studies have suggested that this lesion behaves differently in adults than in children.
  • In the present study, the authors test an orthotopic C6 brainstem glioma model in juvenile and adult rats, and investigate the biological behavior of this lesion in the 2 age groups.
  • METHODS: The C6 glioma cells were stereotactically implanted into the pons of juvenile or adult male rats.
  • Tumor proliferation and the number of apoptotic cells in brainstem gliomas of young and adult rats were determined by immunohistochemical staining with Ki 67 and terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate-mediated nick-end labeling assay.
  • RESULTS: Striking differences in the onset of neurological signs, duration of symptoms, survival time, tumor growth pattern, tumor proliferation, and number of apoptotic cells were found between the gliomas in the 2 groups of rats.
  • The lesions were relatively focal in adult rats but more diffuse in young rats.
  • Furthermore, brainstem gliomas in adult rats were less proliferative and had more apoptotic cells than those in young rats.
  • CONCLUSIONS: The authors found that the C6 brainstem glioma model in young and adult rats closely imitates the course of brainstem glioma in humans both in neurological findings and histopathological characteristics.
  • Their findings also suggest that the different growth pattern and invasiveness of these lesions in children compared with that in adults could be due to different cellular environments in the 2 age groups, and warrants further investigation into the difference in the host response to brainstem gliomas in children and adults.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Age Factors. Animals. Apoptosis. Cell Line, Tumor. Cell Proliferation. Disease Models, Animal. Disease Progression. Kaplan-Meier Estimate. Male. Neoplasm Transplantation / pathology. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1985;76(1-2):12-7 [4003123.001]
  • [Cites] Oncologist. 2004;9(2):197-206 [15047924.001]
  • [Cites] J Neurosurg. 1987 Oct;67(4):483-7 [3309202.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):309-17 [3221258.001]
  • [Cites] Neurosurg Clin N Am. 1990 Jan;1(1):111-21 [2135963.001]
  • [Cites] J Neurotrauma. 1994 Apr;11(2):187-96 [7932797.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] Hum Gene Ther. 1999 Jan 1;10(1):95-101 [10022534.001]
  • [Cites] Arch Dis Child. 1999 Jun;80(6):558-64 [10332008.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1064-9 [10491535.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Feb;27(1):7-12 [15782484.001]
  • [Cites] Childs Nerv Syst. 2005 May;21(5):399-403 [15702357.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E11 [16048287.001]
  • [Cites] J Neurosci Res. 2005 Aug 1;81(3):447-55 [15959903.001]
  • [Cites] Br J Neurosurg. 2005 Apr;19(2):128-36 [16120515.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):253-66 [16195805.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] J Clin Neurosci. 2006 May;13(4):431-7 [16678721.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):546-53 [16734735.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1127-35 [16568342.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):281-7 [16598416.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] J Neurooncol. 2000;46(3):193-203 [10902851.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1569-76 [11013373.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):616-24; discussion 624-5 [11270553.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):206-14 [11359114.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):275-87 [11718260.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):711-5 [11723378.001]
  • [Cites] Vet Pathol. 2002 May;39(3):293-9 [12014493.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):11-5 [3941334.001]
  • (PMID = 18976074.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS054651; United States / NINDS NIH HHS / NS / R01 NS054651-01A2; United States / NINDS NIH HHS / NS / R01 NS054687; United States / NINDS NIH HHS / NS / R01 NS054687-01A2
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS75237; NLM/ PMC2693119
  •  go-up   go-down


35. Windischbauer S, Sedlmayer F: [Radiotherapy of singular brain metastases]. Wien Med Wochenschr; 2010 Feb;160(3-4):77-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy of singular brain metastases].
  • The options consist of surgical resection, stereotactic radiation, and total brain irradiation.
  • We present the case of a young patient with a single brain metastasis of a sigmoidal carcinoma, in stable general condition.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Cranial Irradiation. Palliative Care / methods. Pregnancy Complications, Neoplastic / radiotherapy. Pregnancy Complications, Neoplastic / surgery. Radiosurgery. Sigmoid Neoplasms / radiotherapy. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Neoplasm Staging. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Pregnancy. Retreatment

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2865-72 [15254054.001]
  • [Cites] Strahlenther Onkol. 2010 Feb;186(2):63-9 [20127222.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] Oncologist. 2007 Jul;12(7):884-98 [17673619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):519-26 [12062592.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1169-76 [12654423.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):35-43 [10389878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):621-6 [10949435.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34 [10487566.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1289-94 [16525184.001]
  • (PMID = 20300923.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


36. Qiu J, Ai L, Ramachandran C, Yao B, Gopalakrishnan S, Fields CR, Delmas AL, Dyer LM, Melnick SJ, Yachnis AT, Schwartz PH, Fine HA, Brown KD, Robertson KD: Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest; 2008 Sep;88(9):910-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
  • Malignant gliomas are the most common primary brain tumors in adults and the second most common tumor in children.
  • Morbidity and mortality are high in glioma patients because tumors are resistant to treatment and are highly invasive into surrounding brain tissue rendering complete surgical resection impossible.
  • Here, we study the expression of cystatin E/M in normal brain and show that it is highly and moderately expressed in oligodendrocytes and astrocytes, respectively, but not in neurons.
  • In contrast, 78% of 28 primary brain tumors demonstrated reduced/absent cystatin E/M expression using a tissue microarray and this reduced expression correlated with CST6 promoter hypermethylation.
  • Interestingly, CST6 was expressed in neural stem cells (NSC) and markedly induced upon differentiation, whereas a glioma tumor initiating cell (TIC) line was completely blocked for CST6 expression by promoter methylation.
  • Analysis of primary pediatric brain tumor-derived lines also showed CST6 downregulation and methylation in nearly 100% of 12 cases.
  • These results demonstrate that epigenetic silencing of CST6 is frequent in adult and pediatric brain tumors and occurs in TICs, which are thought to give rise to the tumor.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15893-9 [16565075.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Neuron. 2000 Nov;28(2):385-97 [11144350.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):922-34 [12065604.001]
  • [Cites] J Neurooncol. 2002 May;58(1):21-32 [12160137.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1429-39 [17081116.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1233-42 [17043665.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2409-23 [16952911.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2621-34 [17043644.001]
  • [Cites] Oncogene. 2007 May 10;26(21):3089-94 [17099723.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):447-60 [17610375.001]
  • [Cites] Nat Protoc. 2007;2(9):2265-75 [17853883.001]
  • [Cites] Biochim Biophys Acta. 2007 Dec;1776(2):125-37 [17868999.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):69-80 [18167341.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):21-30 [18184972.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):655-60 [12684707.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):203-15 [15674478.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):175-82 [16356477.001]
  • [Cites] Life Sci. 2006 Jan 18;78(8):898-907 [16150465.001]
  • [Cites] Nat Rev Genet. 2002 Sep;3(9):662-73 [12209141.001]
  • [Cites] Brain Tumor Pathol. 2002;19(1):15-22 [12455884.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8705-12 [12483523.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):327-30 [12591989.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] J Pediatr Nurs. 2003 Apr;18(2):96-102 [12720206.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):134-42 [12850376.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1911-9 [14578190.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] J Neurosci Res. 2003 Dec 15;74(6):838-51 [14648588.001]
  • [Cites] Neurol Clin. 2003 Nov;21(4):897-913 [14743655.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2206-15 [14676833.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2224-30 [14730346.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Mol Cell. 2004 Apr 23;14(2):207-19 [15099520.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):118-31 [15313584.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6957-64 [15466187.001]
  • [Cites] Development. 1989 Feb;105(2):387-400 [2680425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] Neurosci Lett. 1996 Apr 26;208(3):171-4 [8733297.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Clin Exp Metastasis. 1996 Sep;14(4):344-50 [8878408.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10853-8 [9099741.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):89-93 [9738504.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):798-802 [10029065.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6665-74 [16818640.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):159-73 [16442709.001]
  • (PMID = 18607344.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114229-04; United States / NCI NIH HHS / CA / R01 CA114229-03; United States / NCI NIH HHS / CA / R01 CA114229; United States / NCI NIH HHS / CA / CA114229-03; United States / NCI NIH HHS / CA / R01CA102289; United States / NCI NIH HHS / CA / R01 CA102289; United States / NCI NIH HHS / CA / CA114229-04; United States / NCI NIH HHS / CA / R01CA114229
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CST6 protein, human; 0 / Cystatin M; 0 / Cystatins; 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS59304; NLM/ PMC2574902
  •  go-up   go-down


37. Jostel A, Mukherjee A, Hulse PA, Shalet SM: Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf); 2005 Jun;62(6):698-705
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors.
  • OBJECTIVE: Systematic collections of neuroimaging data are nonexistent in brain tumour survivors treated with adult growth hormone replacement therapy (AGHRT).
  • DESIGN: In 1993, our unit implemented a policy of performing brain scans on every brain tumour survivor before starting AGHRT, with repeat neuroimaging at least once after 12-18 months' treatment.
  • PATIENTS: All brain tumour survivors who received AGHRT (60 patients) were included in the analysis.
  • MEASUREMENTS: Evidence and extent of residual tumour, tumour progression, tumour recurrence, and secondary neoplasms (SN) on baseline scan and latest follow-up scan.
  • CONCLUSIONS: Our data do not suggest an increased rate of recurrence or progression of childhood brain tumours during AGHRT.
  • [MeSH-major] Brain Neoplasms. Growth Hormone / deficiency. Growth Hormone / therapeutic use. Hormone Replacement Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasm, Residual / diagnosis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943832.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


38. Armbruster C, Huber M, Prosch H, Dworan N, Attems J: Ewing's sarcoma and peripheral primitive neuroectodermal tumor in adults: different features of a rare neoplasm. Onkologie; 2008 Apr;31(4):179-84
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma and peripheral primitive neuroectodermal tumor in adults: different features of a rare neoplasm.
  • INTRODUCTION: In adults, peripheral primitive neuroectodermal tumors (pPNETs) represent a rare and heterogeneous group of neoplasms exhibiting neuronal and glial differentiation.
  • PATIENTS AND METHODS: We present the clinicopathologic features of four examples of the Ewing's sarcoma (EWS)/pPNET group in adults.
  • RESULTS: Three patients presented with tumors of the thoracopulmonary region, one patient showed EWS of the soft tissue.
  • Microscopically, tumor tissue was composed of round, small, blue cells with fine granular chromatin texture and inconspicuous nucleoli.
  • Tumor cells strongly coexpressed CD99 and vimentin, but due to technical reasons t(22q12) translocation studies proved the presumptive diagnosis of EWS/pPNET in one case only.
  • CONCLUSIONS: As tumors of the EWS/pPNET family behave aggressively, rapid diagnosis is warranted.
  • Since diagnosis of EWS/pPNET requires ancillary studies, it is necessary to consider it even in adult patients.
  • [MeSH-major] Bone Neoplasms / pathology. Brain Neoplasms / pathology. Neuroectodermal Tumors, Primitive / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Rare Diseases

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18418019.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF: Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol; 2008 Jul;88(3):245-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.
  • We investigated the protein expression of three glioma-associated antigens (GAAs) in pediatric brain stem glioma (BSG) and non-brain stem glioma (NBSG) cases with a view to their possible use in immunotherapy.
  • Thirteen of 15 BSGs and all 12 NBSGs expressed at least one of GAAs; and 7 BSGs and 9 NBSGs expressed at least two of these GAAs at higher levels than non-neoplastic brain.
  • There was no association between the tumor grade and levels of GAA expression.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Sep;8(9):987-94 [12172543.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • [Cites] Blood. 2003 Jul 15;102(2):571-6 [12576330.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1294-6 [6277461.001]
  • [Cites] Neurosurgery. 1983 Mar;12(3):298-302 [6302553.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):309-17 [3221258.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1414-21 [8339232.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):470-6 [8635862.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):207-22 [8832463.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):196-201 [9754652.001]
  • [Cites] Childs Nerv Syst. 1999 May;15(5):235-7; discussion 238 [10392494.001]
  • [Cites] Gene Ther. 1999 Feb;6(2):219-26 [10435106.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9160-6 [15604287.001]
  • [Cites] Vaccine. 2005 Jan 4;23(7):884-9 [15603888.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):541-51 [16254188.001]
  • [Cites] Nat Med. 2006 Jan;12(1):99-106 [16327802.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]
  • [Cites] Cancer Immunol Immunother. 2006 Oct;55(10):1294-8 [16315030.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10815-23 [17090523.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):62-9 [10655584.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2449-57 [10811123.001]
  • [Cites] Mol Med. 2000 May;6(5):440-9 [10952023.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Cancer Lett. 2001 Mar 10;164(1):97-104 [11166921.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):869-72 [11221872.001]
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2625-31 [11289140.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):527-30 [11331884.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5964-8 [11507035.001]
  • [Cites] Gene Ther. 2001 Aug;8(15):1157-66 [11509946.001]
  • (PMID = 18324354.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS 40923; United States / NINDS NIH HHS / NS / NS040923-06A15462; United States / NINDS NIH HHS / NS / P01 NS040923; United States / NCI NIH HHS / CA / P01 CA 100327; United States / NCI NIH HHS / CA / P01 CA100327; United States / NINDS NIH HHS / NS / P01 NS040923-06A15462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ NIHMS70086; NLM/ PMC2561297
  •  go-up   go-down


40. Shi AH, Zhu GY, Yu R, Ma HM, Liu CQ, Su X, Sun Y, Cai Y, Xu XN, Zhang SW, Xu B: [Whole brain irradiation for non-small-cell lung cancer with brain metastasis]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):545-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Whole brain irradiation for non-small-cell lung cancer with brain metastasis].
  • OBJECTIVE: To investigate the time of whole brain irradiation and the prognostic factors for non-small lung cancer patients with brain metastasis.
  • METHODS: From August 1996 to December 2003, 147 patients with brain metastasis from non-small cell lung cancer received whole brain irradiation.
  • The patients were divided into two groups: with or without symptoms caused by brain metastasis, each group was then divided into two sub-groups, early whole brain irradiation group (the interval between the diagnosis of brain metastasis and the brain irradiation < or = one month) and late group ( the interval > one month ).
  • Univariate and multivariate analysis (Cox regression) as well as Kaplan-Meier method in SPSS software package 11.5 was used to analyze the data of the 147 patients including 72 with brain metastasis symptom and 75 without.
  • For 72 patients with brain metastasis symptom, the MS of the patients with and without extracranial metastasis was 9.3 months and 11.3 months (P = 0.0036).
  • The MS of patients with early and late whole brain irradiation was 11.4 months and 9.2 months (P = 0.001).
  • Multivariate analysis showed that extracranial metastasis, the interval between the diagnosis of brain metastasis and the whole brain irradiation were independent prognostic factors.
  • However, for 75 patients without brain metastasis symptom, the MS difference of those with early or late whole brain irradiation was not statistically significant (P = 0.1643).
  • CONCLUSION: The extracranial metastasis in non-small cell lung cancer patients with brain metastasis is an independent prognostic factors.
  • Early whole brain irradiation may improve the survival for those with brain metastasis symptoms.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / radiotherapy. Cranial Irradiation. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Time


41. Nataf V, Kerrou K, Balogova S, Pene F, Huchet V, Gutman F, Prignon A, Muresan IP, Giannesini C, Izrael V, Schlienger M, Talbot JN: [Fluoroethylthyrosine 18F PET in the detection of brain tumours]. Bull Cancer; 2010 May;97(5):495-506
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluoroethylthyrosine 18F PET in the detection of brain tumours].
  • PET with fluoroethylthyrosine (FET), amino-acid analogue, has been performed in Germany since the beginning of the decade for molecular and metabolic imaging of brain tumours, since FDG, the glucose analogue which is the reference tracer for clinical PET, has this drawback to be taken-up intensely by cerebral cortex.
  • We report on our preliminary results on the comparison of PET/CT with FET and FDG in 10 evaluable patients presenting with a brain lesion either at diagnosis or after treatment.
  • CONCLUSION: FET is a radiopharmaceutical with clinical usefulness for the diagnosis, delineation and monitoring of brain tumours.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Glioblastoma / radionuclide imaging. Glioma / radionuclide imaging. Humans. Male. Middle Aged. Oligodendroglioma / radionuclide imaging. Positron-Emission Tomography / methods. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374979.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


42. Sadikov E, Bezjak A, Yi QL, Wells W, Dawson L, Millar BA, Laperriere N: Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol); 2007 Sep;19(7):532-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of whole brain re-irradiation for brain metastases--single centre experience.
  • AIMS: There is controversy in published studies regarding the role of repeat whole brain radiation (WBRT) for previously irradiated brain metastases.
  • The aim of our retrospective study was to document the practice at Princess Margaret Hospital with respect to the re-irradiation of patients with progressive or recurrent brain metastatic disease after initial WBRT.
  • MATERIALS AND METHODS: A comprehensive computerised database was used to identify patients treated for brain metastases with more than one course of WBRT between 1997 and 2003.
  • Seventy-two patients were treated with WBRT for brain metastases and retreated with WBRT at a later date.
  • With increased survival and better systemic options for patients with metastatic disease, more patients may be candidates for consideration of repeat WBRT for recurrent brain metastases, but prospective studies are needed to more clearly document their outcomes.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Cranial Irradiation / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662582.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Han JH, Kim DG, Chung HT, Kim CY, Park CK, Chung YS, Paek SH, Yoo MW, Kim BH, Jung HW: Radiosurgery for brain metastasis from advanced gastric cancer. Acta Neurochir (Wien); 2010 Apr;152(4):605-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for brain metastasis from advanced gastric cancer.
  • PURPOSE: We retrospectively evaluated the survival of patients with brain metastases from advanced gastric cancer (AGC) after radiosurgery (RS).
  • METHODS: Between 1998 and 2007, a total of 11 patients (median age, 61 years; range, 36-70) were diagnosed with brain metastasis from AGC and treated with RS.
  • Each of five (46%) patients had two brain metastases.
  • RS was the primary treatment for brain metastases in six patients.
  • Patients who did not undergo WBRT died within 8 months, and the other six patients treated with WBRT at various time intervals from the diagnosis of brain metastases survived, with a median survival time of 19.0 +/- 3.4 months (95% CI, 12.4-25.6).
  • CONCLUSIONS: Radiosurgery seems to be a good alternative to surgical resection for patients with brain metastases from AGC, when performed in conjunction with WBRT.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907917.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


44. Kleinerman RA, Linet MS, Hatch EE, Tarone RE, Black PM, Selker RG, Shapiro WR, Fine HA, Inskip PD: Self-reported electrical appliance use and risk of adult brain tumors. Am J Epidemiol; 2005 Jan 15;161(2):136-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-reported electrical appliance use and risk of adult brain tumors.
  • The authors investigated whether appliances may be associated with adult brain tumors in a hospital-based case-control study at three centers in the United States from 1994 to 1998.
  • There was little evidence of association between brain tumors and curling iron, heating pad, vibrating massager, electric blanket, heated water bed, sound system, computer, television, humidifier, microwave oven, and electric stove.
  • Overall, results indicate that extremely low frequency electromagnetic fields from commonly used household appliances are unlikely to increase the risk of brain tumors.
  • [MeSH-major] Brain Neoplasms / etiology. Glioma / etiology. Household Articles. Meningeal Neoplasms / etiology. Meningioma / etiology. Neuroma, Acoustic / etiology
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Electromagnetic Fields / adverse effects. Female. Humans. Male. Middle Aged. Neoplasms, Radiation-Induced / etiology. Odds Ratio. Risk Factors

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632263.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


45. Saraswathy A, Jayasree RS, Baiju KV, Gupta AK, Pillai VP: Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy. Photomed Laser Surg; 2009 Jun;27(3):425-33
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy.
  • OBJECTIVE: The role of autofluorescence spectroscopy in the detection and staging of benign and malignant brain tumors is being investigated in this study, with an additional aim of determining an optimum excitation wavelength for the spectroscopic identification of brain tumors.
  • MATERIALS AND METHODS: The present study involves in-vitro autofluorescence monitoring of different human brain tumor samples to assess their spectroscopic properties.
  • The autofluorescence measurement at four different excitation wavelengths 320, 370, 410, and 470 nm, were carried out for five different brain tumor types: glioma, astrocytoma, meningioma, pituitary adenoma, and schwannoma.
  • RESULTS: The fluorescence spectra of tumor tissues showed significant differences, both in intensity and in spectral profile, from those of adjacent normal brain tissues at all four excitation wavelengths.
  • Of the four excitation wavelengths being considered, 470 nm appeared to be the optimal wavelength for detecting tissue fluorescence of brain tumor tissues.
  • CONCLUSIONS: In conclusion, the spectroscopic luminescence measurements carried out in this study revealed significant differences between tumor tissue and adjacent normal tissue of human brains for all the tumor types tested, except for pituitary adenoma.
  • From the results of this study we conclude that excitation wavelengths ranging from 410-470 nm are most suitable for the detection of brain tumor tissue.
  • This distinction was not clear at other excitation wavelengths.
  • [MeSH-major] Brain Neoplasms / pathology. Spectrometry, Fluorescence / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Astrocytoma / pathology. Child. Child, Preschool. Discriminant Analysis. Female. Glioma / pathology. Humans. Male. Meningioma / pathology. Middle Aged. Neoplasm Staging. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025404.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Jouvet A, Guyotat J: [Intracranial ependymomas in adult patients. Retrospective analysis of 121 cases from the multicentric French study]. Neurochirurgie; 2007 Jun;53(2-3 Pt 1):66-75
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial ependymomas in adult patients. Retrospective analysis of 121 cases from the multicentric French study].
  • Ependymomas are rare intracranial tumors observed in adults.
  • We report a retrospective study of 121 cases intracranial ependymomas diagnosed between 1990 and 2004 in adult patients.
  • Total gross resection was achieved for 62.8% of tumors.
  • This study demonstrated that extent of surgery and tumor grade are the two main prognostic factors in adult intracranial ependymomas with respect to overall and progression-free survival.
  • Furthermore, our data suggest that postoperative radiotherapy significantly increases progression-free survival in patients with incompletely resected grade II tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neurosurgical Procedures / methods
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. France / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475290.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


47. Yousuf K, Archibald SD: Brain metastases from papillary adenocarcinoma of the thyroid. J Otolaryngol; 2006 Dec;35(6):366-72
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from papillary adenocarcinoma of the thyroid.
  • Brain metastases are very uncommon.
  • RESULTS: Four patients with brain metastasis from their PTA were identified.
  • Thyroglobulin results rose with the development of brain and other distant metastasis for two patients but never increased in the other two patients despite distant metastases at multiple sites.
  • Treatment of brain metastasis was with a combination of surgery, external beam radiation, and radioactive iodine.
  • All patients eventually died of their disease, and the overall survival after the diagnosis of brain metastases was 15.3 months in the four patients.
  • CONCLUSION: This study shows that brain metastasis may or may not be the first site of distant metastasis in patients with PTA.
  • Once brain metastases are diagnosed, palliation with preservation of quality of life becomes the goal of therapy.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Brain Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Radiotherapy, Adjuvant. Retrospective Studies. Thyroglobulin / blood. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380829.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


48. Nasr Ben Ammar C, Chaari N, Kochbati L, Attia I, Ben Hamadi D, Chebbi A, Saadi A, Besbes M, Maalej M: [Brain radionecrosis in patients irradiated for nasopharyngeal carcinoma: about nine cases]. Cancer Radiother; 2007 Sep;11(5):234-40
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain radionecrosis in patients irradiated for nasopharyngeal carcinoma: about nine cases].
  • PURPOSE: To study the clinical, radiological, therapeutic and progressive aspects of brain radionecrosis after treatment for nasopharyngeal carcinoma.
  • RESULTS: Brain radionecrosis was authenticated by brain imaging (CT scan+/-MRI): the imaging was ordered in seven cases to elucidate non-specific neurological signs and two cases were discovered fortuitously.
  • CONCLUSION: Brain radionecrosis is a late complication rarely occurring in patients irradiated for UCNT.
  • [MeSH-major] Brain / pathology. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Age Factors. Analgesics / therapeutic use. Blood-Brain Barrier. Brachytherapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nasopharynx / pathology. Necrosis. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Risk Factors. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631405.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Analgesics
  •  go-up   go-down


49. Chernov MF, Kubo O, Hayashi M, Izawa M, Maruyama T, Usukura M, Ono Y, Hori T, Takakura K: Proton MRS of the peritumoral brain. J Neurol Sci; 2005 Feb 15;228(2):137-42
Hazardous Substances Data Bank. (L)-ASPARTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton MRS of the peritumoral brain.
  • Long-echo (TR: 2000 ms, TE: 136 ms) proton MRS of the cerebral tissue in the vicinity to intracranial lesion was done in 15 patients, mainly with parenchymal brain tumors.
  • Significant decrease of N-acetylaspartate (NAA) (P<0.001) and more frequent presence of lactate (P<0.01) comparing with distant normal white matter were found in the perilesional brain tissue.
  • The level of NAA in the perilesional brain tissue had negative associations with presence of lactate in the lesion (P<0.05), excess of lactate in the lesion compared to perilesional brain (P<0.01), grade of the perilesional edema (P<0.01) and patient's age (P<0.05).
  • Multivariate analysis disclosed that identification of lactate in the lesion is associated with lower relative NAA content in the perilesional brain tissue, independently on the presence or absence of any other factor, including brain edema (P<0.001).
  • In patients with lobar lesions who had at least one epileptic seizure during course of their disease the relative NAA content in the perilesional brain was significantly lower, comparing with those who were seizure-free (P<0.05).
  • Therefore, lactate diffused from the tumor, or other metabolites secreted by lactate-producing neoplasm, should be considered as important contributors to the neuronal dysfunction in the surrounding brain.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Brain / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Brain Edema / etiology. Brain Edema / metabolism. Brain Edema / physiopathology. Epilepsy / etiology. Epilepsy / metabolism. Female. Humans. Lactic Acid / analysis. Lactic Acid / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Nerve Fibers, Myelinated / metabolism. Nerve Fibers, Myelinated / pathology. Predictive Value of Tests. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694194.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; 30KYC7MIAI / Aspartic Acid; 33X04XA5AT / Lactic Acid; 997-55-7 / N-acetylaspartate
  •  go-up   go-down


50. Davey P, Schwartz M, Scora D, Gardner S, O'Brien PF: Fractionated (split dose) radiosurgery in patients with recurrent brain metastases: implications for survival. Br J Neurosurg; 2007 Oct;21(5):491-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated (split dose) radiosurgery in patients with recurrent brain metastases: implications for survival.
  • Radiosurgery is conventionally prescribed for brain metastases with a single dose of radiation.
  • Multivariate analysis showed that the presence of extracranial malignancy, performance status, multiple brain metastases, patient gender and the time from the initial treatment to radiosurgery were independent determinants for survival.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852114.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Fisher JL, Schwartzbaum JA, Wrensch M, Berger MS: Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine. Prog Neurol Surg; 2006;19:54-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine.
  • We evaluate genetic, behavioral, developmental and experiential risk factors for primary adult brain tumors (primarily, astrocytoma and meningioma) using a systematic set of principles adapted from evidence-based medicine standards.
  • In addition to ionizing radiation, rare mutations in highly penetrant genes associated with certain diseases/syndromes, and epilepsy and seizures (which probably result from, rather than cause, adult brain tumors), only the unexplained observation of familial aggregation of astrocytoma has been consistently shown.
  • There is promising renewed interest in associations between infections, allergic conditions and adult brain tumor risk.
  • Our knowledge of the causes of adult brain tumors is limited and should be expanded by results from large, well-designed studies of novel potential risk factors and potential interactions between known and suspected risk factors.
  • [MeSH-major] Brain Neoplasms / etiology. Epidemiologic Methods. Evidence-Based Medicine / methods

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033147.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 142
  •  go-up   go-down


52. Huang AP, Chen JS, Yang CC, Wang KC, Yang SH, Lai DM, Tu YK: Brain stem cavernous malformations. J Clin Neurosci; 2010 Jan;17(1):74-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain stem cavernous malformations.
  • We retrospectively reviewed the clinical experience of 30 patients with brain stem cavernous malformations (BSCM) treated operatively and non-operatively at our hospital between 1983 and 2005 to elucidate the natural history of BSCM and the factors that affect surgical outcome.
  • [MeSH-major] Brain Stem / pathology. Brain Stem / surgery. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Stem Infarctions / etiology. Brain Stem Infarctions / physiopathology. Brain Stem Infarctions / prevention & control. Cerebral Arteries / abnormalities. Cerebral Arteries / pathology. Cerebral Arteries / surgery. Cerebral Veins / abnormalities. Cerebral Veins / pathology. Cerebral Veins / surgery. Child. Female. Humans. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / physiopathology. Intracranial Hemorrhages / prevention & control. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Neurosurgical Procedures / methods. Neurosurgical Procedures / statistics & numerical data. Outcome Assessment (Health Care). Postoperative Hemorrhage / epidemiology. Postoperative Hemorrhage / prevention & control. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20005720.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


53. Jensen TR, Schmainda KM: Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging; 2009 Sep;30(3):481-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided detection of brain tumor invasion using multiparametric MRI.
  • PURPOSE: To determine the potential of using a computer-aided detection method to intelligently distinguish peritumoral edema alone from peritumor edema consisting of tumor using a combination of high-resolution morphological and physiological magnetic resonance imaging (MRI) techniques available on most clinical MRI scanners.
  • MATERIALS AND METHODS: This retrospective study consisted of patients with two types of primary brain tumors: meningiomas (n = 7) and glioblastomas (n = 11).
  • Meningiomas are typically benign and have a clear delineation of tumor and edema.
  • Four classifiers of differing designs were trained using morphological, diffusion-weighted, and perfusion-weighted features derived from MRI to discriminate tumor and edema, tested on edematous regions surrounding tumors, and assessed for their ability to detect nonenhancing tumor invasion.
  • Each classifier was able to identify areas of nonenhancing tumor invasion supported with adjunct images or follow-up studies.
  • CONCLUSION: The combination of features derived from morphological and physiological imaging techniques contains the information necessary for computer-aided detection of tumor invasion and allows for the identification of tumor invasion not previously visualized on morphological, diffusion-weighted, and perfusion-weighted images and maps.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711398.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA028500; United States / NCRR NIH HHS / RR / M01 RR000058; United States / NCI NIH HHS / CA / R21 CA109280; United States / NCI NIH HHS / CA / R01 CA082500; United States / NCRR NIH HHS / RR / M01-RR00058; United States / NCI NIH HHS / CA / R21 CA10928; United States / NCI NIH HHS / CA / R01 CA082500-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS185656; NLM/ PMC4321878
  •  go-up   go-down


54. Tonon E, Scotton PG, Gallucci M, Vaglia A: Brain abscess: clinical aspects of 100 patients. Int J Infect Dis; 2006 Mar;10(2):103-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain abscess: clinical aspects of 100 patients.
  • OBJECTIVE: To verify if, in the last two decades, there have been any changes in epidemiological, clinical, diagnostic, therapeutic and prognostic aspects of patients with brain abscess.
  • METHOD: We studied retrospectively 100 patients discharged over a 17-year period from Ca' Foncello Regional Hospital, Treviso, Italy with a diagnosis of brain abscess.
  • A cerebral neoplasm was the initial neuroradiological diagnosis in 13 patients; 72 patients underwent a neurosurgical procedure.
  • CONCLUSION: With the exception of some epidemiological aspects, which varied from the literature, in spite of the improvements in diagnostic procedures and treatment, no significant changes occurred in the prognosis of patients with brain abscess.
  • [MeSH-major] Brain Abscess
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310393.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


55. Gajera CR, Emich H, Lioubinski O, Christ A, Beckervordersandforth-Bonk R, Yoshikawa K, Bachmann S, Christensen EI, Götz M, Kempermann G, Peterson AS, Willnow TE, Hammes A: LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. J Cell Sci; 2010 Jun 1;123(Pt 11):1922-30
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche.
  • The microenvironment of growth factors in the subependymal zone (SEZ) of the adult brain provides the instructive milieu for neurogenesis to proceed in this germinal niche.
  • We demonstrate that LRP2, a clearance receptor for BMP4 is specifically expressed in ependymal cells of the lateral ventricles in the adult brain.
  • Expression is not seen in ependyma elsewhere in the lateral ventricles or in the dentate gyrus, the second major neurogenic zone of the adult brain.
  • We further show that lack of LRP2 expression in adult mice results in impaired proliferation of neural precursor cells in the SEZ resulting in decreased numbers of neuroblasts reaching the olfactory bulb.
  • Our findings suggest a novel mechanism whereby LRP2-mediated catabolism of BMP4 in the ependyma modulates the microenvironment of the SEZ and enables adult neurogenesis to proceed.
  • [MeSH-major] Adult Stem Cells / metabolism. Bone Morphogenetic Protein 4 / metabolism. Ependyma / metabolism. Low Density Lipoprotein Receptor-Related Protein-2 / metabolism. Stem Cell Niche / metabolism
  • [MeSH-minor] Animals. Cell Proliferation. Cells, Cultured. Gene Expression Regulation. Immunohistochemistry. Inhibitor of Differentiation Proteins / metabolism. Mice. Mice, Mutant Strains. Neoplasm Proteins / metabolism. Neurogenesis / genetics. Olfactory Receptor Neurons / cytology. Sequence Deletion / genetics. Signal Transduction. Smad Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460439.001).
  • [ISSN] 1477-9137
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bmp4 protein, mouse; 0 / Bone Morphogenetic Protein 4; 0 / Inhibitor of Differentiation Proteins; 0 / Low Density Lipoprotein Receptor-Related Protein-2; 0 / Lrp2 protein, mouse; 0 / Neoplasm Proteins; 0 / Smad Proteins; 147785-34-0 / ID3 protein, human
  •  go-up   go-down


56. Kitis O, Altay H, Calli C, Yunten N, Akalin T, Yurtseven T: Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol; 2005 Sep;55(3):393-400
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum apparent diffusion coefficients in the evaluation of brain tumors.
  • OBJECTIVE: To determine whether diffusion-weighted imaging by using minimum apparent diffusion coefficient (ADC(min)) values could differentiate various brain tumors including gliomas, metastases, and lymphomas.
  • MATERIALS AND METHODS: We examined 65 patients with histologically or clinically diagnosed brain tumors (12 low-grade gliomas, 31 high-grade gliomas, 14 metastatic tumors, and 8 lymphomas) using a 1.5 T MR unit.
  • On diffusion-weighted imaging, the ADC(min) values were measured within the tumors and mean values were evaluated regarding statistical differences between groups.
  • RESULTS: The ADC(min) values of low-grade gliomas (1.09+/-0.20 x 10(-3)mm(2)/s) were significantly higher (p<.001) than those of other tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Diagnosis, Differential. Female. Glioma / pathology. Humans. Lymphoma / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129247.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


57. Chura JC, Shukla K, Argenta PA: Brain metastasis from cervical carcinoma. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):141-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis from cervical carcinoma.
  • The aim of this study was to describe the features of patients with brain metastasis from cervical cancer.
  • Twelve patients with brain metastasis from cervical cancer were identified.
  • The incidence of brain metastasis in our population was 0.77%.
  • Median patient age at initial diagnosis of cervical cancer was 43.5 years (range 29-57 years) compared with 44.5 years (range 31-58 years) at identification of brain metastasis.
  • The median interval from diagnosis of cervical cancer to identification of brain metastasis was 17.5 months (range 1.1-96.1 months).
  • Eight patients received whole-brain irradiation and steroids, three received steroids alone, and one underwent surgery, followed by irradiation.
  • All the patients who received whole-brain irradiation experienced improvement in their symptoms.
  • Median survival from diagnosis of brain metastasis to death was 2.3 months (range 0.3-7.9 months).
  • Five patients who received chemotherapy after brain irradiation had a median survival of 4.4 months compared to 0.9 months for those who received no additional treatment after brain irradiation (P= .016).
  • Most patients with brain metastasis from cervical cancer presented with neurologic sequelae.
  • Brain irradiation improved these symptoms.
  • Survival after diagnosis of brain metastasis was poor; however, patients who received chemotherapy after brain irradiation appeared to have improved survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291245.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Stalpers LJ, Dieleman EM, van Westing BR, Postma TJ, van Furth WR: [Diagnosis and treatment of brain tumours]. Ned Tijdschr Tandheelkd; 2009 Apr;116(4):202-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of brain tumours].
  • Primary brain tumours are relatively rare, but brain metastases are a frequent complication of the most common cancers elsewhere in the body (breast, lung, melanoma).
  • Loss of function and excitation of brain nerves i.e. sensory loss, paralysis and pain in the head-and-neck region are specific features in base of skull tumours: meningioma, glomus tumours, vestibular Schwannoma, meningeal metastases by breast cancer, melanoma, and leukaemia, melanoma.
  • In the diagnosis and treatment of brain tumours, special attention is required for rare complications in the head and neck region.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged, 80 and over. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Metastasis. Palliative Care / methods. Prognosis. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438077.001).
  • [ISSN] 0028-2200
  • [Journal-full-title] Nederlands tijdschrift voor tandheelkunde
  • [ISO-abbreviation] Ned Tijdschr Tandheelkd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 1
  •  go-up   go-down


59. Salgado KB, Toscani NV, Silva LL, Hilbig A, Barbosa-Coutinho LM: Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin Exp Metastasis; 2007;24(6):403-10
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas.
  • Brain metastases are linked to poor prognosis.
  • After carcinomas of the lung and breast, malignant melanomas (MM) are the next type of neoplasm with the higher metastatic dissemination involving the central nervous system and that has the worst prognosis after metastasis has been diagnosed.
  • Angiogenesis has been linked to tumor growth and metastasis.
  • Among the immunomarkers of angiogenesis, endoglin (CD105) is the most specific antibody, since it is a marker for tumor endothelium, and expression of CD105 has been observed to be associated with prognosis in several types of tumor, which is not always observed in melanomas.
  • This study investigated angiogenesis in brain metastasis secondary to malignant melanomas and compared these with brain metastasis secondary to carcinomas of the lung and breast, through expression of CD105 (endoglin).
  • The study investigated 93 cases of brain metastasis secondary to MM (33) and carcinomas of the lung (31) and breast (29), assessing endoglin immunoexpression, number of microvessels and diameter of tumor vessels.
  • Tumor microvessels were counted using a modified version of the Chalkley technique.
  • Of the tumors investigated here, malignant melanomas were shown to have the lowest number of microvessels and had intermediate tumor vessel diameter as compared to carcinomas of the lungs and breast.
  • Such results were not expected to be found in neoplasms such as melanomas that, besides presenting high dissemination capacity, have a high index of hemorrhage secondary to brain metastasis.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Melanoma / pathology. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Cross-Sectional Studies. Endoglin. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 May;39(7):881-90 [12706356.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] J Transl Med. 2004 Jun 11;2(1):18 [15193152.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Gene Ther. 2002 May;9(10):631-41 [12032709.001]
  • [Cites] Oral Oncol. 2005 Feb;41(2):147-55 [15695116.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Dec;52(3):199-215 [15582786.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] FASEB J. 2003 Jun;17 (9):984-92 [12773481.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):560-6 [11809710.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):268-75 [11987155.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1564-79 [12142044.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):35-52 [15215160.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):53-7 [11905606.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):508-25 [15563313.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):223-35 [11438469.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Oncology (Williston Park). 1999 Jul;13(7):941-54, 957-61; discussion 961-2, 9 [10442342.001]
  • [Cites] Chest. 2005 Dec;128(6 Suppl):602S-608S [16373858.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Apr;54(1):53-61 [15780907.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Apr;43(4):912-8 [11923228.001]
  • [Cites] Obstet Gynecol. 2000 Aug;96(2):224-8 [10908767.001]
  • [Cites] APMIS. 2002 Feb;110(2):177-85 [12064874.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):331-7 [1383607.001]
  • [Cites] Cancer Treat Rev. 2004 Oct;30(6):515-20 [15325032.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1195-206 [11181686.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):413-30 [15563306.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):102-11 [15661540.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3906-27 [12228212.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4959-67 [10987313.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 2):89-115 [9053298.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):268-73 [1637135.001]
  • [Cites] Histopathology. 2005 Aug;47(2):186-94 [16045780.001]
  • [Cites] Curr Opin Pharmacol. 2002 Aug;2(4):403-14 [12127873.001]
  • [Cites] J Pathol. 1991 Jul;164(3):241-4 [1890549.001]
  • [Cites] Am J Pathol. 1995 Oct;147(4):1049-56 [7573350.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Semin Oncol. 1977 Mar;4(1):81-91 [841354.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1826-31 [11919240.001]
  • [Cites] Mayo Clin Proc. 1994 Nov;69(11):1062-8 [7967760.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):856-61 [10029075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13 [11121063.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 17564791.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / ENG protein, human; 0 / Endoglin; 0 / Receptors, Cell Surface
  •  go-up   go-down


60. Jehi LE, Lüders HO, Naugle R, Ruggieri P, Morris H, Foldvary N, Wyllie E, Kotagal P, Bingaman B, Dinner D, Prayson R, Diehl B, Alexopoulos A, Bautista J, Busch R: Temporal lobe neoplasm and seizures: how deep does the story go? Epileptic Disord; 2008 Mar;10(1):56-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal lobe neoplasm and seizures: how deep does the story go?
  • There is a well-described association between the occurrence of developmental tumors and the presence of cortical dysplasia in the neighboring brain tissue.
  • The main surgical approaches in the treatment of medically refractory epilepsy related to such developmental tumors include a lesionectomy versus a tailored cortical resection, often guided by an invasive evaluation.
  • It illustrates the pros and cons of various surgical approaches, and discusses some pathophysiological aspects of developmental tumors, dysplasia and epilepsy.
  • [MeSH-major] Brain Neoplasms / physiopathology. Epilepsy, Temporal Lobe / physiopathology. Seizures / physiopathology. Temporal Lobe
  • [MeSH-minor] Adult. Amobarbital. Brain / pathology. Dominance, Cerebral. Female. Humans. Hypnotics and Sedatives. Magnetic Resonance Imaging. Neurosurgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Amobarbital .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367435.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; GWH6IJ239E / Amobarbital
  •  go-up   go-down


61. Kwon KY, Kong DS, Lee JI, Nam DH, Park K, Kim JH: Outcome of repeated radiosurgery for recurrent metastatic brain tumors. Clin Neurol Neurosurg; 2007 Feb;109(2):132-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of repeated radiosurgery for recurrent metastatic brain tumors.
  • CONCLUSION: Recurrence is common for patients with metastatic brain tumors after initial radiosurgery.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930821.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Aprile G, Zanon E, Tuniz F, Iaiza E, De Pauli F, Pella N, Pizzolitto S, Buffoli A, Piga A, Skrap M, Fasola G: Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol; 2009 Mar;135(3):451-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases.
  • Due to this remarkable life extension, the incidence of brain metastases, though still low, is progressively increasing over time.
  • There is little reported data on the optimal strategy to manage brain lesions from colorectal cancer.
  • METHODS: To explore the role of an aggressive approach to colorectal cancer brain metastases, we retrospectively collected and analyzed data from 30 patients who underwent neurosurgical resection + whole-brain radiotherapy between March 1998 and December 2006.
  • At the time of the analysis, 29 out of 30 patients had died, with a median survival time after brain metastasectomy of 167 days (8-682).
  • CONCLUSIONS: Neurosurgical management of symptomatic brain metastases from colorectal cancer is feasible, relatively safe, and offers a chance of prolonged survival.
  • [MeSH-major] Brain Neoplasms / secondary. Colorectal Neoplasms / pathology. Neoplasm Metastasis / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Dissection / methods. Female. Humans. Italy. Male. Middle Aged. Neurosurgical Procedures. Patient Selection. Retrospective Studies. Survival Analysis. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2006 Aug;55 Suppl 3:iii1-8 [16835351.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2047-53 [8683235.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):765-73 [8625178.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1677-85 [10223560.001]
  • [Cites] Lancet Neurol. 2005 May;4(5):289-98 [15847842.001]
  • [Cites] Eur J Neurol. 2006 Jul;13(7):674-81 [16834697.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):771-6 [10622506.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1925-33 [14584076.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7 [8040016.001]
  • [Cites] Oncologist. 2007 Jul;12(7):884-98 [17673619.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] JAMA. 2006 Nov 1;296(17):2089-90; author reply 2090-1 [17077371.001]
  • [Cites] Curr Oncol. 2007 Aug;14(4):131-43 [17710205.001]
  • [Cites] Curr Opin Oncol. 2005 Nov;17(6):588-92 [16224238.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] J Pathol. 1986 Nov;150(3):195-203 [3806280.001]
  • [Cites] Tumori. 2005 Mar-Apr;91(2):163-7 [15948545.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Pathol. 2005 Mar;58(3):237-42 [15735152.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):158-65 [18459179.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):453-63 [8876887.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23 (36):9441-2 [16361649.001]
  • [Cites] Ann Thorac Surg. 2007 Jul;84(1):324-38 [17588454.001]
  • [Cites] J Neurooncol. 1983;1(3):203-9 [6678969.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6 [10863071.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 18779977.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, Kortmann RD: Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol; 2009 Aug;71(2):165-79
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET).
  • Medulloblastoma and supratentorial primitive neuroectodermal tumors are rare diseases in adults.
  • Due to this rarity, few prospective clinical trials have been conducted on medulloblastoma in adults, investigations being based exclusively on retrospective studies; the populations considered in literature are small, and the different treatments given span decades, during which diagnostic procedures, neurosurgical skills and radiotherapy techniques have changed.
  • Unlike pediatric patients, adult medulloblastoma patients have been treated according to risk-adapted therapeutic strategies in only a few series and despite risk-tailored treatments, 20-30% of patients experience recurrence.
  • [MeSH-major] Brain Neoplasms. Medulloblastoma. Neuroectodermal Tumors, Primitive
  • [MeSH-minor] Adolescent. Adult. Child. Female. Genetic Predisposition to Disease. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303318.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 71
  •  go-up   go-down


64. Omura T, Nawashiro H, Osada H, Shima K, Tsuda H, Shinsuke A: Pilomyxoid astrocytoma of the fourth ventricle in an adult. Acta Neurochir (Wien); 2008 Nov;150(11):1203-6; discussion 1206

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma of the fourth ventricle in an adult.
  • This tumour corresponds to a WHO grade II neoplasm whereas pilocytic astrocytoma corresponds to WHO grade I.
  • We have encountered an infratentorial tumour with pilomyxoid features in an adult.
  • Brain MRI revealed a mass occupying the fourth ventricle.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology
  • [MeSH-minor] Adult. Age Distribution. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / physiopathology. Humans. Hyperacusis / etiology. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Tinnitus / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958385.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Tseng JH, Merchant E, Tseng MY: Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales. Surg Neurol; 2006 Sep;66(3):258-63; discussion 263
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales.
  • BACKGROUND: To investigate the effects of SES and geographic variations on survival for adult patients with glioma, we analyzed data from 30489 patients from the Cancer Registry in England and Wales.
  • METHODS: Median survival and CSRs for 8 variables (age, sex, morphology, World Health Organization [WHO] grade, tumor site, SES, geographic regions, and periods of diagnosis) are calculated using the Kaplan-Meier method.
  • CONCLUSIONS: Although age and tumor characteristics (morphology, WHO grade, tumor site) are well-known prognostic factors, SES and geographic variations also play a slight but significant role, and for more cost-effective allocation of health resources, alleviation on these 2 modifiable factors should be considered.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioma / epidemiology. Outcome Assessment (Health Care) / statistics & numerical data
  • [MeSH-minor] Adult. Age Distribution. Age Factors. Cost-Benefit Analysis. England / epidemiology. Ependymoma / diagnosis. Ependymoma / epidemiology. Ependymoma / physiopathology. Female. Geography. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / physiopathology. Prognosis. Registries / statistics & numerical data. Resource Allocation / trends. Sex Distribution. Socioeconomic Factors. State Medicine. Survival Rate. Wales / epidemiology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935629.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M, Yamasaki M: D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol; 2006 Jul;19(7):974-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells.
  • Some brain tumors such as anaplastic ependymoma, some medulloblastomas, glioblastoma, pineal germinoma, craniopharyngioma, choroid plexus papilloma, choroid plexus carcinoma, and meningioma showed positive immunoreactivity with D2-40.
  • Therefore, D2-40 antibody is considered a useful marker for research on developing brain and diagnosis of brain tumors, differentiation between choroid plexus carcinoma and metastatic carcinoma.
  • [MeSH-major] Antibodies, Monoclonal. Antigens, Neoplasm / analysis. Brain Neoplasms / immunology. Cerebellum / immunology. Telencephalon / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation. Cells, Cultured. Child, Preschool. Fetus / immunology. Gestational Age. Humans. Immunohistochemistry. Infant. Middle Aged. Neurons / cytology. Neurons / immunology. Prosencephalon / cytology. Stem Cells / cytology. Stem Cells / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648867.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


67. Kleinschmidt-Demasters BK, Cummings TJ, Hulette CM, Morgenlander JC, Corboy JR: Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder. J Neuropathol Exp Neurol; 2009 Apr;68(4):432-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder.
  • Leukoencephalopathy with cerebral calcifications and cysts is characterized by progressive formation of brain cysts that can generate a mass effect simulating a neoplasm.
  • We and others have reported LCC cases in adults.
  • We report 2 additional adult-onset cases of LCC.
  • These cases expand the spectrum of adult-onset LCC, the etiology of which is unknown.
  • [MeSH-major] Brain / pathology. Calcinosis / complications. Cysts / complications. Dementia, Vascular / complications
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287308.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Amichetti M, Lay G, Dessì M, Orrù S, Farigu R, Orrù P, Farci D, Melis S, Cagliari Neuro-Oncology Group: Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. Tumori; 2005 Mar-Apr;91(2):163-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma.
  • AIMS AND BACKGROUND: Carcinoma of the colon-rectum is an infrequent cause of brain metastases, constituting 1.5% of all metastatic lesions to the brain.
  • We reviewed our experience in the treatment of brain metastases from colorectal cancer to define the efficacy of whole brain radiation therapy as a palliative measure in this setting of patients.
  • METHODS: Twenty-three consecutive cases of brain metastasis from colorectal cancer treated between 1999 and 2004 were identified in the files of the Division of Radiotherapy of the A Businco Regional Oncological Hospital, Cagliari.
  • Their records were reviewed for patient and tumor characteristics and categorized according to the RTOG RPA classes.
  • In 3 patients only the cause of death was the brain metastasis.
  • CONCLUSIONS: Despite the disappointing survival time, external radiation therapy to the whole brain proved to be an efficacious palliative treatment for patients with multiple or inoperable brain metastasis from colorectal cancer.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948545.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


69. Xia HS, Han SY, Li P, Liu ZC, Tang PY: [Stereotactic radiotherapy for multiple brain metastases]. Ai Zheng; 2005 Jun;24(6):711-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic radiotherapy for multiple brain metastases].
  • BACKGROUND & OBJECTIVE: Stereotactic radiotherapy (SRT) has obvious advantages in treating intracranial tumors, but there are few reports about application of SRT to multiple intracranial tumors.
  • This paper summarized the therapy outcome of patients with multiple brain metastases, and evaluated the efficacy and application of SRT.
  • METHODS: Clinical data of 136 patients with multiple brain metastases received radiotherapy from Jun.
  • Of the 136 patients, 52(38.2%) received conventional radiotherapy alone (CR group), 84(61.8%) received SRT or SRT plus whole brain radiotherapy (SRT group).
  • RESULTS: Clinical effective rate, and elimination rate of brain metastases (diameter of > 20 mm) were significantly higher in SRT group than in CR group (96.4% vs. 86.5%, P=0.02; 70.4% vs. 36.0%, P=0.007).
  • Persistent brain edema rate was 8.3% in SRT group, and 9.6% in CR group (P=0.767).
  • Intracranial tumor recurrence rate was 25.0% in SRT group, and 19.4% in CR group (P=0.653).
  • CONCLUSION: Reasonable application of SRT could improve life quality and treatment outcome of patients with multiple brain metastases, reduce intracranial tumor recurrence and radiation damage, and prolong patients'survival time.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Lung Neoplasms / pathology. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Edema / etiology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate


70. Kondziolka D, Martin JJ, Flickinger JC, Friedland DM, Brufsky AM, Baar J, Agarwala S, Kirkwood JM, Lunsford LD: Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer; 2005 Dec 15;104(12):2784-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survivors after gamma knife radiosurgery for brain metastases.
  • BACKGROUND: Stereotactic radiosurgery, with or without whole-brain radiation therapy, has become a valued management choice for patients with brain metastases, although their median survival remains limited.
  • The authors evaluated all brain metastasis in patients who lived for > or = 4 years after radiosurgery to determine clinical and treatment patterns potentially responsible for their outcome.
  • METHODS: Six hundred seventy-seven patients with brain metastases underwent 781 radiosurgery procedures between 1988 and 2000.
  • Data from the entire series were reviewed; and, if patients had > or = 4 years of survival, then they were evaluated for information on brain and extracranial treatment, symptoms, imaging responses, need for further care, and management morbidity.
  • Two or more organ sites outside the brain were involved in 18 patients (41%), the primary tumor plus lymph nodes were involved in 10 patients (23%), only the primary tumor was involved in 9 patients (20%), and only brain disease was involved in 7 patients (16%), indicating that extended survival was possible even in patients with multiorgan disease.
  • Serial imaging of 133 tumors showed that 99 tumors were smaller (74%), 22 tumors were unchanged (17%), and 12 tumors were larger (9%).
  • Four patients had a permanent neurologic deficit after brain tumor management, and six patients underwent a resection after radiosurgery.
  • Compared with the patients who had limited survival (< 3 mos), long-term survivors had a higher initial KPS (P = 0.01), fewer brain metastases (P = 0.04), and less extracranial disease (P < 0.00005).
  • CONCLUSIONS: Although the expected survival of patients with brain metastases may be limited, selected patients with effective intracranial and extracranial care for malignant disease can have prolonged, good-quality survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neoplasm Invasiveness / pathology. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16288488.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Wyszko E, Rolle K, Nowak S, Zukiel R, Nowak M, Piestrzeniewicz R, Gawrońska I, Barciszewska MZ, Barciszewski J: A multivariate analysis of patients with brain tumors treated with ATN-RNA. Acta Pol Pharm; 2008 Nov-Dec;65(6):677-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multivariate analysis of patients with brain tumors treated with ATN-RNA.
  • Malignant gliomas express preferentially a number of surface markers that may be exploited as therapeutic targets, such as tenascin-C, an extracellular matrix glycoprotein contributes to tumor cell adhesion, invasion, migration and proliferation.
  • Here we present the data for 46 patients suffering from brain tumor.
  • MRI and CT follow up studies showed growth tumor delay or lack of its recurrence symptoms, due to inhibition of TN-C synthesis.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. RNA, Double-Stranded / therapeutic use. Tenascin / metabolism
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Follow-Up Studies. Glioblastoma / physiopathology. Glioblastoma / therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Quality of Life. RNA Interference. RNA, Messenger / metabolism. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172848.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / RNA, Double-Stranded; 0 / RNA, Messenger; 0 / Tenascin
  •  go-up   go-down


72. Moulin-Romsée G, D'Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, Menten J, Bormans G, Van Laere K: Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging; 2007 Dec;34(12):2082-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?
  • BACKGROUND: Static imaging of amino acids does not allow differentiation of low versus high grade brain tumours.
  • METHODS: Thirty-four patients with primary brain glioma and histopathological confirmation were retrospectively studied using 40 min dynamic MET-PET with 220 MBq 11C-methionine.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / pathology. Glioma / diagnostic imaging. Glioma / pathology. Methionine. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Neoplasm Staging. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Nov;225(2):567-74 [12409596.001]
  • [Cites] J Nucl Med. 2001 Aug;42(8):1144-50 [11483672.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] NeuroRx. 2005 Apr;2(2):333-47 [15897954.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):580-9 [11847106.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9 [15650870.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):932-9 [16604346.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1432-7 [16908552.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):205-12 [9935078.001]
  • (PMID = 17763978.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


73. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH: Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol; 2007 Aug;84(1):49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature.
  • Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors which occur almost exclusively in infants and young children.
  • There have been only 17 cases of AT/RT in adults reported in the medical literature and the rarity of this tumor makes the diagnosis in adults difficult.
  • We describe a case of an AT/RT of the spinal cord in an adult.
  • In consultation with senior pathologists at other institutions, the lesion was initially diagnosed as a rhabdoid meningioma.
  • The patient underwent three additional surgical procedures for recurrent disease throughout the neuraxis secondary to leptomeningeal spread of the tumor.
  • To our knowledge, this is the first case of a spinal atypical teratoid/rhabdoid tumor in an adult fully documented with molecular, immunohistochemical, cytogenetic and autopsy findings.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. Chromosomes, Human, Pair 22 / genetics. DNA-Binding Proteins / genetics. Neoplasm Recurrence, Local / pathology. Rhabdoid Tumor / pathology. Spinal Cord Neoplasms / pathology. Teratoma / pathology. Transcription Factors / genetics
  • [MeSH-minor] Adult. Cervical Vertebrae. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Monosomy / diagnosis. Monosomy / genetics. SMARCB1 Protein

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):665-70 [15769941.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4012-9 [15899790.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2661-74 [16537910.001]
  • [Cites] Neurochirurgie. 1999 Sep;45(3):237-42 [10567965.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Clin Neurosci. 2003 May;10 (3):325-8 [12763338.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50 [16301525.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • (PMID = 17377740.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down


74. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V: Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast; 2006 Apr;15(2):219-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
  • The intention of this retrospective analysis was to describe the characteristics of patients with brain metastasis (BM) receiving trastuzumab for HER2 overexpressing metastatic breast cancer (MBC).
  • There was no correlation of the development of BM with regard to tumor grading and patient age.
  • In patients who developed BM, the median interval between visceral and brain metastasis was 14 months (range 0-69 months).
  • [MeSH-major] Brain Neoplasms / epidemiology. Breast Neoplasms / epidemiology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Drug Administration Schedule. Female. Germany / epidemiology. Humans. Immunohistochemistry. Medical Records. Middle Aged. Neoplasm Metastasis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Analysis. Trastuzumab


75. Bottke D, Wiegel T, Kreusel KM, Höcht S, Hinkelbein W: Is a diagnostic CT of the brain indicated in patients with choroidal metastases before radiotherapy? Strahlenther Onkol; 2005 Apr;181(4):251-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is a diagnostic CT of the brain indicated in patients with choroidal metastases before radiotherapy?
  • BACKGROUND AND PURPOSE: There is no evidence in the literature about the incidence of synchronous brain metastases in patients with choroidal metastases.
  • This is of major importance, because the radiation fields of choroidal metastases and, later on, brain metastases, if treated consecutively, are partly overlapping, thus potentially increasing the rate of late side effects such as brain necrosis.
  • The goal of this study was to determine the frequency of synchronous brain metastases.
  • All patients were staged before treatment with a computed tomography of the brain (CCT).
  • No patient showed clinical signs of brain metastases.
  • RESULTS: 13 out of 50 patients (26%) had brain metastases in the CCT leading to radiotherapy of the brain and choroidal metastases in one volume.
  • CONCLUSION: A CCT is indicated at the diagnosis of choroidal metastases for screening of synchronous brain metastases.
  • The incidence is about 25%, and the diagnosis of brain metastases results in a different target volume: the whole brain including the posterior parts of the eyes compared to the posterior parts of the eyes alone.
  • Therefore, the risk of late side effects could be reduced compared with an additional later radiotherapy of the whole brain with partly overlapping fields.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Choroid Neoplasms / radiotherapy. Choroid Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy Dosage. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827695.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Chernov MF, Skvortzova TY, Brodskaya ZL: Reduction of blood flow in the brain stem and cerebellum caused by petroclival tumors. Neurol Med Chir (Tokyo); 2005 Jan;45(1):31-5; discussion 36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of blood flow in the brain stem and cerebellum caused by petroclival tumors.
  • Blood flow in the brain stem (BSBF) and cerebellum (CerBF) was investigated by positron emission tomography in 12 patients with petroclival tumors (study group) and 14 healthy volunteers (control group). (15)O-labeled water was used as the radioisotope tracer.
  • Five of 12 patients in the study group exhibited more than 20% reduction of CerBF ipsilateral to the tumor, whereas no such asymmetry was disclosed in any subject in the control group (p < 0.01).
  • Sex, age, and tumor histology had no statistically significant association with the level of BSBF.
  • No statistically significant association between BSBF and the type of postoperative course was found, whereas four of the five patients with more than 20% reduction of CerBF ipsilateral to the tumor had prominently increased cerebellar ataxia after removal of the neoplasm.
  • Preoperative investigation of the cerebral blood flow may be important for the prediction of outcome after surgical resection of petroclival tumors.
  • [MeSH-major] Brain Stem / blood supply. Cerebellum / blood supply. Cerebrovascular Circulation / physiology. Cranial Fossa, Posterior. Skull Base Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699618.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Rushing EJ, Smith AB, Smirniotopoulos JG, Douglas AF, Zeng W, Azumi N: Occult leptomeningeal large cell medulloblastoma in an adult. Clin Neuropathol; 2009 May-Jun;28(3):188-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult leptomeningeal large cell medulloblastoma in an adult.
  • We report the first case of this entity in an adult that proved to be an unsuspected primary leptomeningeal tumor.
  • Postmortem examination of the brain was notable for necrotic cerebellar tonsils, but demonstrated no evidence of an intraparenchymal mass lesion.
  • CONCLUSIONS: Our experience with this unique case illustrates the challenges of diagnosing a primary leptomeningeal neoplasm.
  • This case also underscores the importance of maintaining a high degree of suspicion for leptomeningeal neoplasms in patients who present with imaging studies suspicious for Chiari I malformation.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Meningeal Neoplasms / pathology
  • [MeSH-minor] Adult. Arnold-Chiari Malformation / complications. Fatal Outcome. Humans. Intervertebral Disc Displacement / complications. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537136.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Quigley MR, Fuhrer R, Karlovits S, Karlovits B, Johnson M: Single session stereotactic radiosurgery boost to the post-operative site in lieu of whole brain radiation in metastatic brain disease. J Neurooncol; 2008 May;87(3):327-32
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single session stereotactic radiosurgery boost to the post-operative site in lieu of whole brain radiation in metastatic brain disease.
  • PURPOSE: Whole brain radiation (WBXRT) reduces the incidence of local and distant recurrence following resection of metastatic brain disease but does not prolong life and may entail neurocognitive decline.
  • METHODS: We reviewed all patients at our institution that were treated with SRS to the post-operative bed following resection of a metastatic brain deposit.
  • Factors which improved survival were solitary tumor, age <65 and RPA 1, although none achieved statistical significance.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / prevention & control. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cranial Irradiation. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Period. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2529-36 [12829672.001]
  • [Cites] J Neurosurg. 1996 May;84(5):748-54 [8622147.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2483-91 [16757720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7 [8040016.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):333-8 [11872278.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):519-26 [12062592.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326 [12762877.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):810-7 [17011454.001]
  • [Cites] Am J Gastroenterol. 1959 Jun;31(6):673-83 [13649667.001]
  • [Cites] Neurology. 1989 Jun;39(6):789-96 [2725874.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Neurosurgery. 2005 May;56(5):1021-34; discussion 1021-34 [15854250.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):210-6 [8331402.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1260-6 [17401015.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • (PMID = 18183353.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Lu Z, Cao Y, Wang Y, Zhang Q, Zhang X, Wang S, Li Y, Xie H, Jiao B, Zhang J: Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China. J Neurooncol; 2007 Oct;85(1):65-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China.
  • The single nucleotide polymorphisms (SNPs) in the promoter region of matrix metalloproteinase (MMP) genes may influence tumor occurrence and progression via modifying mRNA transcription and protein expression.
  • The study aims to explore the association of the SNPs in MMP-1, 3 and MMP-9 promoters with susceptibility to adult brain astrocytoma in northern China.
  • Genotyping for the MMP-1 -1607 2G/1G, MMP-3 -1171 5A/6A, and MMP-9 -1562 C/T SNPs were performed by PCR-RFLP methods among 236 adult astrocytoma patients and 366 healthy controls.
  • The similar results were obtained when stratified by gender and age at tumor diagnosis (< or =45 or >45 years).
  • The present study suggested that, the MMP-1 -1607 1G/1G genotype and MMP-1 1G-MMP-3 6A haplotype may play protective role in the development of adult astrocytoma in northern Chinese, whereas the MMP-3 -1171 5A/6A and MMP-9 -1562 C/T polymorphisms may not be independent factors to influence susceptibility to adult astrocytoma in this population.
  • [MeSH-major] Astrocytoma / epidemiology. Astrocytoma / genetics. Brain Neoplasms / epidemiology. Brain Neoplasms / genetics. Matrix Metalloproteinase 1 / genetics. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 9 / genetics. Polymorphism, Genetic / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Case-Control Studies. China / epidemiology. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Genetic Linkage / genetics. Genotype. Haplotypes. Humans. Polymorphism, Single Nucleotide. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 2005 Sep;113(9):1209-11 [16140629.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):418-23 [10598806.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):357-61 [12385578.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):105-12 [15696970.001]
  • [Cites] Circulation. 1999 Apr 13;99(14 ):1788-94 [10199873.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6430-3 [12438229.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):481-6 [15528217.001]
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Br Heart J. 1995 Mar;73(3):209-15 [7727178.001]
  • [Cites] Clin Chem. 2003 Nov;49(11):1940-2 [14578330.001]
  • [Cites] Mol Hum Reprod. 2002 May;8(5):494-501 [11994547.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13055-60 [8662692.001]
  • [Cites] Int J Cancer. 2002 Dec 10;102(5):526-9 [12432557.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):372-4 [12845675.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Lung Cancer. 2005 Aug;49(2):155-61 [15949868.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2519-24 [15319302.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):667-71 [9818179.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3820-3 [12473595.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):851-9 [11404367.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):251-2 [12398887.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):461-7 [15006924.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):49-55 [14550952.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):92-6 [16278009.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):197-204 [15609121.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):469-80 [10027405.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1600-5 [10845878.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8468-73 [15548720.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):366-70 [10209950.001]
  • [Cites] Matrix Biol. 1997 Mar;15(8-9):535-41 [9138286.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):19-25 [15565457.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):65-72 [14756443.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2385-9 [15832405.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):98-103 [15950766.001]
  • [Cites] Brain Res. 2006 Nov 6;1118(1):6-12 [16956593.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6459-65 [16024651.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):781-5 [15957163.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • (PMID = 17502998.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


80. Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM 3rd, Warfield SK, Kikinis R, Bromfield EB: Morphological characteristics of brain tumors causing seizures. Arch Neurol; 2010 Mar;67(3):336-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological characteristics of brain tumors causing seizures.
  • OBJECTIVE: To quantify size and localization differences between tumors presenting with seizures vs nonseizure neurological symptoms.
  • We performed magnetic resonance imaging-based morphometric analysis and nonparametric mapping in patients with brain tumors.
  • PATIENTS OR OTHER PARTICIPANTS: One hundred twenty-four patients with newly diagnosed supratentorial glial tumors.
  • MAIN OUTCOME MEASURES: Volumetric and mapping methods were used to evaluate differences in size and location of the tumors in patients who presented with seizures as compared with patients who presented with other symptoms.
  • RESULTS: In high-grade gliomas, tumors presenting with seizures were smaller than tumors presenting with other neurological symptoms, whereas in low-grade gliomas, tumors presenting with seizures were larger.
  • Tumor location maps revealed that in high-grade gliomas, deep-seated tumors in the pericallosal regions were more likely to present with nonseizure neurological symptoms.
  • In low-grade gliomas, tumors of the temporal lobe as well as the insular region were more likely to present with seizures.
  • CONCLUSIONS: The influence of size and location of the tumors on their propensity to cause seizures varies with the grade of the tumor.
  • In high-grade gliomas, rapidly growing tumors, particularly those situated in deeper structures, present with non-seizure-related symptoms.
  • In low-grade gliomas, lesions in the temporal lobe or the insula grow large without other symptoms and eventually cause seizures.

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] J Neurosurg. 2009 Apr;110(4):696-708 [19133753.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):614-23 [11026445.001]
  • [Cites] Eur Neurol. 2001;45(1):46-51 [11150841.001]
  • [Cites] Hum Brain Mapp. 2002 Jan;15(1):1-25 [11747097.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Epilepsia. 2002 Jul;43(7):727-33 [12102675.001]
  • [Cites] Can J Neurol Sci. 2003 May;30(2):106-12 [12774949.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):636-41 [12963754.001]
  • [Cites] Neuroimage. 2003 Dec;20(4):2343-56 [14683734.001]
  • [Cites] Neurol India. 2003 Dec;51(4):503-6 [14742933.001]
  • [Cites] Neurology. 2004 May 25;62(10):1783-7 [15159478.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jun;146(6):589-94: discussion 594 [15168227.001]
  • [Cites] Neurosurgery. 2004 Aug;55(2):358-70; discussion 370-1 [15271242.001]
  • [Cites] Epilepsia. 2004 Sep;45(9):1079-90 [15329073.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1983 May;58(5):672-7 [6339686.001]
  • [Cites] Acta Neurochir (Wien). 1990;103(1-2):47-51 [2360466.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):496-501 [1851971.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Oct;54(10):915-20 [1744647.001]
  • [Cites] J Comput Assist Tomogr. 1994 Mar-Apr;18(2):192-205 [8126267.001]
  • [Cites] Neurosurgery. 1994 May;34(5):815-23; discussion 823-4 [8052378.001]
  • [Cites] Arch Neurol. 1995 Jul;52(7):717-24 [7619029.001]
  • [Cites] J Neurosurg. 1996 Aug;85(2):263-71 [8755755.001]
  • [Cites] Magn Reson Imaging. 1995;13(8):1153-62 [8750330.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Neuroimage. 1996 Dec;4(3 Pt 1):223-35 [9345513.001]
  • [Cites] Neuroimage. 1997 Feb;5(2):83-96 [9345540.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):98-102 [9624245.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Jan;18(1):32-42 [10193695.001]
  • [Cites] Brain. 1955;78(4):445-70 [13293263.001]
  • [Cites] Epilepsia. 2005 Apr;46(4):590-1 [15816958.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):212-5 [16043788.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):211-5 [16193395.001]
  • [Cites] Radiology. 2006 May;239(2):506-13 [16641355.001]
  • [Cites] Tumori. 2006 Sep-Oct;92(5):407-11 [17168433.001]
  • [Cites] Eur J Neurol. 2007 Apr;14(4):391-8 [17388986.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):582-92 [17432707.001]
  • [Cites] Lancet Neurol. 2007 May;6(5):421-30 [17434097.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Sep;109(7):634-8 [17601658.001]
  • [Cites] Neuroimage. 2007 Sep 1;37(3):866-75 [17616402.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):227-35 [18240916.001]
  • [Cites] Neurol Sci. 2008 Apr;29(2):77-83 [18483704.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):825-34 [18976071.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • (PMID = 20212231.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA067165-11; None / None / / U41 RR019703-01A2; United States / NCRR NIH HHS / RR / U41 RR019703; None / None / / P41 RR013218-12; United States / NCI NIH HHS / CA / 5P01CA067165-11; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCI NIH HHS / CA / CA067165-09A2; United States / NCI NIH HHS / CA / P01 CA067165-09A2; United States / NCI NIH HHS / CA / P01 CA067165-11; United States / NCRR NIH HHS / RR / U41 RR019703-01A2; United States / NCRR NIH HHS / RR / P41 RR013218-12; United States / NCRR NIH HHS / RR / P41RR13218; United States / NCI NIH HHS / CA / P01 CA067165-03; United States / NCI NIH HHS / CA / P01 CA067165
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS215136; NLM/ PMC2995444
  •  go-up   go-down


81. Komuro T, Okamoto S: Pure intracerebral mass lesion of adult T-cell leukemia/lymphoma--case report. Neurol Med Chir (Tokyo); 2010;50(6):492-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure intracerebral mass lesion of adult T-cell leukemia/lymphoma--case report.
  • A 48-year-old female presented with a rare case of adult T-cell leukemia/lymphoma (ATL) occurring as only intracerebral mass lesion manifesting as progressively worsening headaches, transient mild weakness of the left lower extremity, bilateral papilledema, and left homonymous hemianopsia.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Occipital Lobe / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587977.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Järvelä S, Parkkila S, Bragge H, Kähkönen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H: Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer; 2008;8:1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX in oligodendroglial brain tumors.
  • METHODS: This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed oligoastrocytomas).
  • RESULTS: 80% of the tumors showed CA IX expression by immunohistochemistry.
  • Tumors with moderate or strong CA IX expression had decreased level of cell proliferation compared to weak or no CA IX expression (median 2.9 vs. 5.8, p = 0.015).
  • CA IX correlated with two antioxidative enzymes, manganese superoxide dismutase (MnSOD) and regulatory gammaglutamylcysteine synthetase (GLCL-R): CA IX expression was significantly higher in MnSOD-positive tumors (p = 0.008) and decreased in GLCL-R-positive tumors (p = 0.044).
  • CONCLUSION: CA IX was proved to be an independent prognostic indicator in oligodendroglial brain tumors, and it also correlates reversely with cell proliferation.
  • It may have a role in the biology of oligodendrogliomas, and most interestingly, as it is mainly expressed in tumor tissue, CA IX could serve as a target molecule for anticancer treatments.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism. Oligodendroglioma / enzymology
  • [MeSH-minor] Adult. Cell Proliferation. Follow-Up Studies. Humans. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6567-71 [15475445.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):398-408 [9024293.001]
  • [Cites] Cancer Res. 1982 May;42(5):1955-61 [7066906.001]
  • [Cites] Am J Med. 1991 Sep 30;91(3C):14S-22S [1928205.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Aug;16(4):261-8 [7524516.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):279-85 [9665489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1197-207 [15752902.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Nov 1;15(21):4872-6 [16165351.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1750-7 [11410516.001]
  • [Cites] Mol Hum Reprod. 2001 Jul;7(7):611-6 [11420383.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:421-55 [11441809.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):643-9 [11690711.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):29-37 [11804280.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1205-12 [11861405.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Apr;28(2):89-94 [11972795.001]
  • [Cites] Med Res Rev. 2003 Mar;23(2):146-89 [12500287.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):155-64 [12744469.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600-19 [12796054.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23 [14684331.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):995-1004 [15010840.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):869-73 [15012984.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • (PMID = 18173856.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2245965
  •  go-up   go-down


83. Noël G, Mazeron JJ: [Reirradiation in primary or secondary brain tumors]. Cancer Radiother; 2010 Oct;14(6-7):421-37
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reirradiation in primary or secondary brain tumors].
  • The purpose of this review was to analyze data available on reirradiation for high-grade glioma or brain metastasis.
  • In brain metastases, total brain irradiation seems useful if metastases are multiple and the patient in good condition.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Aged, 80 and over. Brain / radiation effects. Brain Edema / drug therapy. Brain Edema / etiology. Carcinoma / radiotherapy. Carcinoma / secondary. Carcinoma / surgery. Child. Child, Preschool. Clinical Trials as Topic. Dose Fractionation. Humans. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Prognosis. Radiation Injuries / drug therapy. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiosurgery. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy Dosage. Radiotherapy, Conformal. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20797888.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


84. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB: Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol; 2009 Dec;95(3):377-382
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.
  • In general, surgical resection for pilocytic astrocytoma is thought to be curative with tumor recurrence or malignant transformation being relatively rare.
  • However, there have been very few studies specifically looking at the prognosis for adult patients diagnosed with pilocytic astrocytoma.
  • To evaluate the frequency of recurrence and malignant transformation of pilocytic astrocytoma in adults, we performed a retrospective analysis of all adult patients who underwent surgical resection for this tumor at our institution over a period of 10 years.
  • This study provides further evidence that the clinical course of a subset of adult patients with pilocytic astrocytoma will not be benign.
  • The potential for rapid tumor recurrence and malignant transformation necessitates careful post-operative follow-up for adult patients with this tumor.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):613-6 [15799194.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2799-808 [17973253.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):907-16 [16170340.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(3):341-6 [10819266.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] J Neurosurg. 1985 Sep;63(3):382-6 [4020465.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):90-3 [3751698.001]
  • [Cites] Childs Nerv Syst. 2005 Nov;21(11):940-4 [16044344.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Br J Ophthalmol. 2008 Jan;92(1):40-6 [17962395.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):657-65 [19271226.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1153-60 [15001258.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):606-9 [2034360.001]
  • [Cites] Surg Neurol. 1993 May;39(5):360-4 [8493594.001]
  • (PMID = 19533024.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai SK, Wenz F: Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1311-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Memory function before and after whole brain radiotherapy in patients with and without brain metastases.
  • PURPOSE: To prospectively compare the effect of prophylactic and therapeutic whole brain radiotherapy (WBRT) on memory function in patients with and without brain metastases.
  • METHODS AND MATERIALS: Adult patients with and without brain metastases (n = 44) were prospectively evaluated with serial cognitive testing, before RT (T0), after starting RT (T1), at the end of RT (T2), and 6-8 weeks (T3) after RT completion.
  • Data were obtained from small-cell lung cancer patients treated with prophylactic cranial irradiation, patients with brain metastases treated with therapeutic cranial irradiation (TCI), and breast cancer patients treated with RT to the breast.
  • CONCLUSIONS: The results of our study have shown that WBRT causes cognitive dysfunction immediately after the beginning of RT in patients with brain metastases only.
  • At 6-8 weeks after the end of WBRT, cognitive dysfunction was seen in patients with and without brain metastases.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Memory / radiation effects. Protons / therapeutic use. Radiotherapy / adverse effects
  • [MeSH-minor] Clinical Trials as Topic. Cobalt Radioisotopes / economics. Cobalt Radioisotopes / therapeutic use. Costs and Cost Analysis. Humans. Neoplasm Metastasis. Neoplasm Staging. United States

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):975; author reply 975-6 [19480978.001]
  • (PMID = 18448270.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Protons
  •  go-up   go-down


86. Sillitoe RV, Stephen D, Lao Z, Joyner AL: Engrailed homeobox genes determine the organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum. J Neurosci; 2008 Nov 19;28(47):12150-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Engrailed homeobox genes determine the organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum.
  • Underlying the seemingly uniform cellular composition of the adult mammalian cerebellum (Cb) are striking parasagittal stripes of gene expression along the medial-lateral (ML) axis that are organized with respect to the lobules that divide the Cb along the anterior-posterior (AP) axis.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comp Neurol. 2000 Jan 17;416(3):383-97 [10602096.001]
  • [Cites] Neuroscience. 2008 May 15;153(3):721-32 [18403128.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1377-89 [10837030.001]
  • [Cites] J Neurosci. 2001 May 1;21(9):3126-34 [11312297.001]
  • [Cites] J Comp Neurol. 2001 Jul 16;436(1):42-51 [11413545.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):235-44 [11799142.001]
  • [Cites] J Neurosci. 2003 Jun 15;23(12):5105-12 [12832534.001]
  • [Cites] J Neurosci. 2003 Jul 23;23(16):6576-85 [12878699.001]
  • [Cites] J Neurosci. 2003 Dec 10;23(36):11342-51 [14672998.001]
  • [Cites] Genes Dev. 1988 Mar;2(3):361-71 [2454212.001]
  • [Cites] J Comp Neurol. 1990 Jan 1;291(1):79-102 [1688891.001]
  • [Cites] J Comp Neurol. 1990 Jan 22;291(4):538-52 [2329190.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1239-43 [1672471.001]
  • [Cites] J Comp Neurol. 1992 Sep 1;323(1):128-36 [1430312.001]
  • [Cites] Neuron. 1993 Jun;10(6):1007-18 [8318226.001]
  • [Cites] Development. 1994 Mar;120(3):695-706 [7909289.001]
  • [Cites] J Comp Neurol. 1994 Jul 1;345(1):33-45 [8089276.001]
  • [Cites] Development. 1994 Jul;120(7):2065-75 [7925010.001]
  • [Cites] Development. 1994 Aug;120(8):2081-90 [7925012.001]
  • [Cites] Anat Embryol (Berl). 1994 Nov;190(5):417-28 [7887492.001]
  • [Cites] Science. 1995 Aug 4;269(5224):679-82 [7624797.001]
  • [Cites] Development. 1995 Dec;121(12):3935-45 [8575294.001]
  • [Cites] J Neurophysiol. 1996 Dec;76(6):4169-74 [8985909.001]
  • [Cites] J Neurosci. 1997 Oct 15;17(20):7881-9 [9315908.001]
  • [Cites] Development. 1997 Nov;124(22):4425-33 [9409661.001]
  • [Cites] J Comp Neurol. 1998 May 18;394(4):431-44 [9590553.001]
  • [Cites] J Neurosci. 1999 Jul 1;19(13):5370-9 [10377347.001]
  • [Cites] J Comp Neurol. 1999 Sep 13;412(1):95-111 [10440712.001]
  • [Cites] Eur J Neurosci. 1999 Aug;11(8):2720-30 [10457168.001]
  • [Cites] Neuroscience. 1999;93(3):1083-94 [10473273.001]
  • [Cites] J Comp Neurol. 1952 Oct;97(2):281-356 [12999992.001]
  • [Cites] Nature. 1963 Nov 23;200:793 [14087025.001]
  • [Cites] Neuron. 2005 Jan 6;45(1):27-40 [15629700.001]
  • [Cites] Prog Brain Res. 2005;148:125-38 [15661186.001]
  • [Cites] Prog Brain Res. 2005;148:283-97 [15661197.001]
  • [Cites] J Comp Neurol. 2005 Oct 10;491(1):69-78 [16127699.001]
  • [Cites] J Comp Neurol. 2006 May 20;496(3):303-13 [16566000.001]
  • [Cites] J Comp Neurol. 2006 Aug 1;497(4):670-82 [16739198.001]
  • [Cites] Development. 2006 Jul;133(14):2719-29 [16774995.001]
  • [Cites] Exp Neurol. 2007 Jan;203(1):205-12 [17022974.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):168-76 [17151600.001]
  • [Cites] J Comp Neurol. 2007 Jun 10;502(5):857-71 [17436294.001]
  • [Cites] Development. 2007 Jun;134(12):2325-35 [17537797.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:549-77 [17506688.001]
  • [Cites] Neural Dev. 2007;2:26 [18053187.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):RC45 [10594089.001]
  • (PMID = 19020009.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / Autism Speaks / / AS1658; United States / NIMH NIH HHS / MH / MH085726-01; United States / NIMH NIH HHS / MH / R01 MH085726; United States / NIMH NIH HHS / MH / R01 MH085726-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / En1 protein, mouse; 0 / Heat-Shock Proteins; 0 / Homeodomain Proteins; 0 / Hspb1 protein, mouse; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / engrailed 2 protein; 0 / zebrin II; 108688-71-7 / neurofilament protein H; EC 3.1.4.11 / Phospholipase C beta; EC 3.1.4.11 / Plcb4 protein, mouse
  • [Other-IDs] NLM/ NIHMS184147; NLM/ PMC2864318
  •  go-up   go-down


87. Lee HY, Lee KS, Kim BT, Cho YS, Lee EJ, Yi CA, Chung MJ, Kim TS, Kwon OJ, Kim H: Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci; 2009 Dec;24(6):1132-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma.
  • We aimed to evaluate prospectively the efficacy of positron emission tomography (PET)/computed tomography (CT) plus brain magnetic resonance imaging (MRI) for detecting extrathoracic metastases in lung adenocarcinoma.
  • Metastatic evaluations were feasible for 442 consecutive patients (M:F=238:204; mean age, 54 yr) with a lung adenocarcinoma who underwent PET/CT (CT, without IV contrast medium injection) plus contrast-enhanced brain MRI.
  • The presence of metastases in the brain was evaluated by assessing brain MRI or PET/CT, and in other organs by PET/CT.
  • Diagnostic efficacies for metastasis detection with PET/CT plus brain MRI and with PET/CT only were calculated on a per-patient basis and compared from each other.
  • Of 442 patients, 88 (20%, including 50 [11.3%] with brain metastasis) had metastasis.
  • Regarding sensitivity of overall extrathoracic metastasis detection, a significant difference was found between PET/CT and PET/CT plus brain MRI (68% vs. 84%; P=0.03).
  • As for brain metastasis detection sensitivity, brain MRI was significantly higher than PET/CT (88% vs. 24%; P<0.001).
  • By adding MRI to PET/CT, brain metastases were detected in additional 32 (7% of 442 patients) patients.
  • In lung adenocarcinoma patients, significant increase in sensitivity can be achieved for detecting extrathoracic metastases by adding dedicated brain MRI to PET/CT and thus enhancing brain metastasis detection.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Non-Small-Cell Lung. Lung Neoplasms. Neoplasm Metastasis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. ROC Curve. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2003 Jan;123(1 Suppl):137S-146S [12527573.001]
  • [Cites] Lung Cancer. 2002 Jul;37(1):87-94 [12057872.001]
  • [Cites] Am Rev Respir Dis. 1979 Nov;120(5):1025-9 [228572.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Chest. 1984 Dec;86(6):850-3 [6094117.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1474-80 [3047337.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12(2):293-300 [1902031.001]
  • [Cites] CA Cancer J Clin. 1992 Jan-Feb;42(1):19-38 [1728335.001]
  • [Cites] Thorax. 1994 Jan;49(1):14-9 [8153934.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Jul;152(1):225-30 [7599828.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Jul;156(1):320-32 [9230769.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):505-9 [10078629.001]
  • [Cites] Chest. 1999 Mar;115(3):714-9 [10084481.001]
  • [Cites] Radiology. 1999 Sep;212(3):803-9 [10478250.001]
  • [Cites] Radiology. 2005 Sep;236(3):1011-9 [16014441.001]
  • [Cites] Radiology. 2007 Mar;242(3):882-8 [17229875.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1068-77 [17311309.001]
  • [Cites] Eur Respir J. 2007 May;29(5):995-1002 [17331966.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):498-509 [17729341.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):178S-201S [17873168.001]
  • [Cites] J Thorac Oncol. 2008 Feb;3(2):140-4 [18303434.001]
  • [Cites] Radiology. 2008 Aug;248(2):632-42 [18552311.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):425-33; discussion 433-4 [11235682.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1344-9 [11230477.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Cancer. 1974 Feb;33(2):492-6 [4812766.001]
  • (PMID = 19949671.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2775863
  • [Keywords] NOTNLM ; Brain / Lung Neoplasms / Magnetic Resonance Imaging / Neoplasm Metastasis / Neoplasm Staging / PET/CT Scan
  •  go-up   go-down


88. DeLorenze GN, McCoy L, Tsai AL, Quesenberry CP Jr, Rice T, Il'yasova D, Wrensch M: Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. BMC Cancer; 2010 May 19;10:215
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma.
  • METHODS: Adult patients diagnosed with malignant glioma during 1991-1994 and 1997-2001 were enrolled in a population-based study.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Causes Control. 2009 Oct;20(8):1255-60 [19363672.001]
  • [Cites] Integr Cancer Ther. 2004 Dec;3(4):294-300 [15523100.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9062-9 [15489897.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Eur J Clin Nutr. 2005 Dec;59(12):1387-96 [16160702.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4531-41 [16618782.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] J Nutr. 2006 Jun;136(6):1477-82 [16702307.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 1;41(3):464-72 [16843827.001]
  • [Cites] BMC Cancer. 2006;6:148 [16749939.001]
  • [Cites] Free Radic Biol Med. 2007 Jun 1;42(11):1715-22 [17462539.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2885-93 [17146445.001]
  • [Cites] PLoS One. 2007;2(6):e576 [17593975.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Sep;133(9):627-33 [17457608.001]
  • [Cites] J Neurol Sci. 2007 Sep 15;260(1-2):49-56 [17475281.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1679-83 [18059031.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):288-95 [18412241.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):773-83 [18505970.001]
  • [Cites] Free Radic Biol Med. 2008 Oct 15;45(8):1178-89 [18718523.001]
  • [Cites] Turk Neurosurg. 2008 Oct;18(4):336-44 [19107679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • [Cites] Free Radic Biol Med. 2000 Apr 1;28(7):1143-56 [10832077.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Ann N Y Acad Sci. 2000;899:191-208 [10863540.001]
  • [Cites] Oncologist. 2002;7(1):17-33 [11854544.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3729-35 [12097282.001]
  • [Cites] J Neurooncol. 2002 May;57(3):193-200 [12125982.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2496-501 [15059904.001]
  • [Cites] Free Radic Biol Med. 2004 Aug 1;37(3):287-303 [15223063.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Alcohol Alcohol Suppl. 1987;1:75-82 [3426757.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):43-6 [2081237.001]
  • [Cites] IARC Sci Publ. 1991;(105):197-203 [1855850.001]
  • [Cites] Prog Food Nutr Sci. 1991;15(4):183-217 [1784736.001]
  • [Cites] J Fla Med Assoc. 1993 Mar;80(3):181-4 [8387566.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):857-62 [8487050.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):453-9 [7852106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5258-65 [7777494.001]
  • [Cites] Zentralbl Neurochir. 1996;57(2):76-88 [8779273.001]
  • [Cites] Biochem Soc Trans. 1996 Aug;24(3):790-5 [8878849.001]
  • [Cites] Cancer Causes Control. 1997 Jan;8(1):13-24 [9051318.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):13-28 [9266437.001]
  • [Cites] Public Health Nutr. 2009 Dec;12(12):2438-47 [19371448.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • (PMID = 20482871.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA052689; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants
  • [Other-IDs] NLM/ PMC2880992
  •  go-up   go-down


89. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol; 2009;48(1):52-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
  • MATERIAL AND METHODS: We retrospectively determined the efficacy and safety of a combination of bevacizumab and irinotecan in a consecutive series of 52 heavily pre-treated patients with recurrent high-grade brain tumours.
  • DISCUSSION: We conclude that the combination of bevacizumab and irinotecan shows acceptable safety and is a clinically relevant choice of therapy in heavily pre-treated patients with recurrent high-grade brain tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Oncol. 2009;48(1):6-8 [18932097.001]
  • (PMID = 19031176.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


90. Fox BD, Patel A, Suki D, Rao G: Surgical management of metastatic sarcoma to the brain. J Neurosurg; 2009 Jan;110(1):181-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of metastatic sarcoma to the brain.
  • OBJECT: Metastatic sarcoma to the brain is rare and represents a therapeutic challenge due to its relative resistance to radio- and chemotherapy.
  • The authors reviewed a series of patients with metastatic sarcoma to the brain treated surgically to determine outcomes and identify predictors of survival in these patients.
  • METHODS: A retrospective review of prospectively collected data was undertaken on patients undergoing surgery between 1993 and 2005 for metastatic sarcoma to the brain at The University of Texas, M.D.
  • RESULTS: During the study period, 62 patients underwent 84 operations for metastatic sarcoma to the brain.
  • In patients with alveolar soft-part sarcoma, there was a significantly increased survival advantage compared with all other histological subgroups.
  • CONCLUSIONS: The authors' results suggest that in selected patients, resection of metastatic sarcoma to the brain is associated with a relatively low risk of operative death and results in improvement in neurological function.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neurosurgical Procedures. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult


91. Treuer H, Klein D, Maarouf M, Lehrke R, Voges J, Sturm V: Accuracy and conformity of stereotactically guided interstitial brain tumour therapy using I-125 seeds. Radiother Oncol; 2005 Nov;77(2):202-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and conformity of stereotactically guided interstitial brain tumour therapy using I-125 seeds.
  • OBJECTIVE: To assess the accuracy of the stereotactic implantation procedure of catheters containing I-125 seeds in brain tumours and investigate the effect of catheter deviations on the dose distribution in patients.
  • Intraoperative X-ray images were used to measure deviations of implanted I-125 seed catheters from their planned positions and the influence on dose conformity, tumour surface dose and dose burden of surrounding healthy brain tissue was determined.
  • CONCLUSIONS: Stereotactically guided interstitial irradiation with I-125 seeds can be used to treat brain tumours and metastases with high conformity comparable to radiosurgery.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Iodine Radioisotopes / therapeutic use. Radiosurgery / methods. Radiotherapy Planning, Computer-Assisted / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Humans. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Radiotherapy, Computer-Assisted / methods. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Stereotaxic Techniques. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209895.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


92. Figarella-Branger D, Metellus P, Barrié M, Maues de Paula A, Fernandez C, Polivka M, Vital A, Labrousse F, Vignaud JM, Laquerrière A, Rousselet MC, Lacroix C, Saikali S, Chapon F, Gontier MF, Chrétien F, Babin P, Rigau V, Vandenbos F, Peoc'h M, Kujas M, Chinot O, Gouvernet J, Giorgi R, Guyotat J, Jouvet A: [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors]. Neurochirurgie; 2007 Jun;53(2-3 Pt 1):76-84
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors].
  • BACKGROUND: Intracranial ependymomas are rare in adults and histopathological prognostic factors are poorly determined.
  • MATERIAL: Between 1990 and 2004, 216 adult patients with newly diagnosed ependymomas were treated in 19 French centers.
  • The potential prognostic value (overall survival OS and disease free survival DFS) of the following histological parameters was examined: perivascular pseudorosettes, ependymal rosettes, hyalinized vessels, mitotic index, microvascular proliferation, necrosis, area of increased cellularity, nuclear atypia, brain invasion and Mib-1 labelling index.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Ependymoma / mortality. Ependymoma / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Neoplasm Staging. Neurosurgical Procedures. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445840.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


93. Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F: Brain metastases in patients with advanced breast cancer. Anticancer Res; 2007 Jul-Aug;27(4C):2865-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in patients with advanced breast cancer.
  • BACKGROUND: The incidence of brain metastases (BM) is apparently rising in patients with advanced breast cancer (ABC).
  • On multivariate analysis, HER2/neu over expression and Ki-67 -20% were independent predictive factors of brain relapse (Odds Ratio (OR) 2.55, 95% confidence intervals (CI) 1.10-5.94 and OR 2.97, 95% CI 1.01-8.73, respectively).
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cell Growth Processes / physiology. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis


94. Guyotat J, Metellus P: [Intracranial ependymomas in adult patients. Prognostic factors, place of surgery and complementary treatment]. Neurochirurgie; 2007 Jun;53(2-3 Pt 1):85-94
MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial ependymomas in adult patients. Prognostic factors, place of surgery and complementary treatment].
  • Prognostic factors and optimal therapy for adult intracranial ependymoma are still debated.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Complementary Therapies / methods. Ependymoma / mortality. Ependymoma / pathology. Neurosurgical Procedures / methods
  • [MeSH-minor] France / epidemiology. Humans. Neoplasm Recurrence, Local / epidemiology. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418281.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


95. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM: A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol; 2009 Jan;91(2):183-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
  • This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic glioma when treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC).
  • Treatment with poly-ICLC continued until tumor progression.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12 [18262679.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Immunology. 2008 Aug;124(4):480-8 [18248388.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Interferon Res. 1982;2(1):1-4 [6180095.001]
  • [Cites] Tex Rep Biol Med. 1981-1982;41:653-62 [6189230.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1058-65 [3155990.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2483-91 [2411797.001]
  • [Cites] J Biol Response Mod. 1985 Oct;4(5):475-80 [2416882.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):640-9 [2418162.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):664-8 [2418164.001]
  • [Cites] Gynecol Oncol. 1986 Jul;24(3):359-61 [3721308.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1341-2 [3768878.001]
  • [Cites] J Urol. 1987 Feb;137(2):202-6 [3806804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3005-10 [1591717.001]
  • [Cites] J Neurosurg. 1992 Jul;77(1):120-6 [1318961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):75-83 [7721642.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Methods Mol Biol. 2007;383:277-301 [18217692.001]
  • (PMID = 18850068.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062421-08; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Inducers; 24939-03-5 / Poly I-C; 25104-18-1 / Polylysine; 59789-29-6 / poly ICLC; 9004-32-4 / Carboxymethylcellulose Sodium
  • [Other-IDs] NLM/ NIHMS291833; NLM/ PMC3104130
  •  go-up   go-down


96. Ozawa N, Muragaki Y, Nakamura R, Hori T, Iseki H: Shift of the pyramidal tract during resection of the intraaxial brain tumors estimated by intraoperative diffusion-weighted imaging. Neurol Med Chir (Tokyo); 2009 Feb;49(2):51-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shift of the pyramidal tract during resection of the intraaxial brain tumors estimated by intraoperative diffusion-weighted imaging.
  • The present study evaluated the shift of the pyramidal tract during resection of 17 proximal intraaxial brain tumors.
  • The position of the white matter bundles containing the pyramidal tract was estimated on the coronal images before and after resection of the neoplasm, and both quantitative and directional evaluation of its displacement was done.
  • The magnitude of the pyramidal tract displacement due to removal of the neoplasm varied from 0.5 to 8.7 mm (mean 4.4 +/- 2.5 mm) on the lesion side and from 0 to 3.6 mm (mean 1.3 +/- 1.1 mm) on the normal side (p < 0.001).
  • Tumor location in regards to the pyramidal tract was significantly associated with the direction of the pyramidal tract displacement (p < 0.05).
  • Outward shift occurred in 10 out of 13 cases of the lateral neoplasms, whereas in all 4 superomedial tumors inward shift was marked.
  • In conclusion, the direction of the pyramidal tract displacement during resection of the proximal intraaxial brain tumors is mainly determined by position of the neoplasm, but can be unpredictable in some cases, which necessitates use of subcortical brain mapping and intraoperative imaging, particularly iDW imaging with updated neuronavigation.
  • [MeSH-major] Brain Mapping / methods. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Neuronavigation / methods. Pyramidal Tracts / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / physiopathology. Female. Humans. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Neoplasm Invasiveness. Nerve Fibers, Myelinated / pathology. Neurosurgical Procedures / methods. Predictive Value of Tests. Preoperative Care / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246864.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


97. Takci E, Sengul G, Akar A, Uslu H, Alper F, Erdogan F, Aydin IH: Alveolar echinococcosis of the brain in five patients. J Clin Neurosci; 2008 Oct;15(10):1105-9
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar echinococcosis of the brain in five patients.
  • Cerebral alveolar echinococcis is a biologically aggressive infestation that mimics a malignant neoplasm radiologically and macroscopically.
  • [MeSH-major] Brain Diseases / parasitology. Echinococcosis / diagnosis
  • [MeSH-minor] Adult. Anthelmintics / therapeutic use. Brain Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Alveolar Echinococcosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653340.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Anthelmintics
  •  go-up   go-down


98. Schwartzbaum JA, Ahlbom A, Lönn S, Warholm M, Rannug A, Auvinen A, Christensen HC, Henriksson R, Johansen C, Lindholm C, Malmer B, Salminen T, Schoemaker MJ, Swerdlow AJ, Feychting M: An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):559-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors.
  • BACKGROUND: Glutathione transferases (GST) detoxify environmental and endogenous compounds and levels of two polymorphic GST proteins, GSTM3 and GSTP1, are high in the brain.
  • Previous studies of GSTM3 and GSTP1 polymorphisms and adult brain tumor risk have produced inconsistent results, whereas the GSTM3 -63 variant is newly identified and, therefore, has not yet been studied in this context.
  • We therefore examined associations between GSTM3 -63, GSTM3 *A/*B, GSTP1 105, and GSTP1 114 variants and adult brain tumor risk and the interaction of the effects of these same polymorphisms with cigarette smoking.
  • In addition, the enzymes NQO1 and CYP1A1 alter susceptibility to oxidative brain damage.
  • RESULTS: We found no associations between the GSTM3, GSTP1, NQO1, CYP1A1, GSTM1, or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C (Val-Ala) GSTP1 105/114 haplotype and glioma [odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.54, 0.99], nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking.
  • CONCLUSIONS: Overall, we observed no strong evidence for an association between GST or related enzyme polymorphisms and adult brain tumor risk.
  • [MeSH-major] Brain Neoplasms / genetics. Glutathione Transferase / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Cytochrome P-450 CYP1A1 / genetics. Denmark / epidemiology. England / epidemiology. Female. Finland / epidemiology. Genotype. Haplotypes. Humans. Logistic Models. Male. Middle Aged. NAD(P)H Dehydrogenase (Quinone) / genetics. Population Surveillance. Risk Factors. Smoking / adverse effects. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372252.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


99. Tabatabai G, Bähr O, Möhle R, Eyüpoglu IY, Boehmler AM, Wischhusen J, Rieger J, Blümcke I, Weller M, Wick W: Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain; 2005 Sep;128(Pt 9):2200-11
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells.
  • Here we report that adult human and murine haematopoietic PCs display a tropism for intracerebral gliomas but not for normal brain tissue in mice.
  • Thus, we define here the molecular mechanism underlying the glioma tropism of the probably most easily accessible PC population suitable for cancer therapy, that is, adult haematopoietic PC.
  • [MeSH-major] Brain Neoplasms / pathology. Chemotaxis. Glioma / pathology. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / cytology
  • [MeSH-minor] Adult. Animals. Chemokine CXCL12. Chemokines, CXC / physiology. Humans. Matrix Metalloproteinase 9 / physiology. Mice. Mice, Nude. Neoplasm Transplantation. Stem Cell Factor / physiology. Transforming Growth Factor beta / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947066.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Stem Cell Factor; 0 / Transforming Growth Factor beta; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


100. Huang CF, Chiou SY, Wu MF, Tu HT, Liu WS, Chuang JC: Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery. J Neurosurg; 2010 Dec;113 Suppl:97-104
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery.
  • The authors hypothesized that loss of tumor cells after Gamma Knife surgery (GKS) may alter the ADC value and used diffusion weighted MR imaging (DW imaging) to evaluate cellular changes in brain tumors to detect their treatment response and the efficacy of GKS.
  • METHODS: In this paper the authors describe a prospective trial involving 86 patients harboring 38 solid or predominantly solid brain metastases, 30 meningiomas, and 24 acoustic neuromas that were treated by GKS.
  • Follow-up MR images and clinical outcomes were reviewed at 3-month intervals for metastatic lesions and at 6-month intervals for benign tumors.
  • Calcification (p = 0.006) and tumor recurrence (p = 0.025) significantly prevented a rise in the ADC level.The mean ADC value for all solid acoustic neuromas was 1.06 ± 0.17 × 10-3 mm2/sec before GKS.
  • At the last mean MR imaging follow-up there appeared to be tumor enlargement in 3 patients (12.5%); however, since the ADC values in these patients were significantly higher than the preradiosurgery values, the finding was considered to be a sign of radiation necrosis rather than tumor recurrence.
  • The mean ADC value of metastatic tumors was 1.05 ± 0.12 × 10-3 mm2/sec before GKS.
  • Magnetic resonance imaging showed that 89% of these tumors had been controlled by GKS.
  • In some patients in whom imaging findings are equivocal, ADC values may also be used to distinguish radiation-induced necrosis from tumor recurrence.(DOI: 10.3171/2010.7.GKS10864)
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Diffusion Magnetic Resonance Imaging / methods. Image Processing, Computer-Assisted / methods. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Echo-Planar Imaging. Female. Humans. Male. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222290.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement